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“Many things cause terror and wonder, yet nothing is more terrifying and wonderful
than man. [...] Possessing means of invention, a skillfulness beyond expectation, now
toward evil he moves, now toward good. By integrating the laws of the earth and justice
under oath sworn to the gods, he is lofty of city. Citiless is the man with whom igno-
bility because of his daring dwells. May he never reside at my hearth or think like me,
whoever does such things.”




Quantifying immune contexture of tumors using imaging
and sequencing data
Cancer treatment has always been a main issue in medicine, though, thanks to the
recent discovery and involvement of novel technologies able to amplify the research
spectrum of action, the efforts have been increased towards precision oncology. Can-
cer immunology is a promising approach, supposed to reduce the invasiveness for
the patient due to its peculiarity of eliciting the human immune response to act se-
lectively against the tumor in a personalized way for each single patient, depending
on his genetic tumor environment. The tumor immune contexture, defined as the
type and density of tumor-infiltrating immune cells, has a strong impact on patients’
prognosis and response to therapy. In particular, high infiltration of cytotoxic CD8+ T
cells, which has the capability of recognize and kill tumor cells, has been associated
with a good prognosis. Thus, the quantification of CD8+ T cells is of paramount im-
portance for the stratification of cancer patients and for the development of effective
combination therapies.
In this thesis, two techniques are described and combined experimentally to quan-
tify CD8+ T cells and their subtypes: RNA sequencing (RNA-Seq) and immunohisto-
chemistry (IHC) imaging. First, we developed a deconvolution algorithm based on
support-vector regression and on a novel signature matrix, which computes the rel-
ative cell fractions of naïve, central memory, and effector memory CD8+ T cells from
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bulk tumor RNA-seq data. After validation with simulated data, the deconvolution
method was applied to published data from glioblastoma tumors, proving its appli-
cability to data from both fresh-frozen and archived tumor samples. Second, we opti-
mized a bioinformatics pipeline for the quantification of total CD8+ T cells from im-
munohistochemistry images of human tumors and we applied it to the analysis of 29
melanoma samples. Given the availability of large collections of archived tumor sam-
ples exploited for image pathology and, more recently, for RNA-seq, these methods
represent valuable tools for the efficient extraction of immunological features from
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The immune system is a collection of organs, cells, and substances that help protect-
ing the human body from infections and other general diseases.
It keeps track of all the substances normally found in the body. Any new substance
that the immune cell, for instance the T lymphocyte, does not recognize as part of the
so-called self-environment raises an alarm, urging the body to attack it. For example,
bacteria produce substances, such as certain proteins, that are not normally found
in the human body. The immune system recognizes these substances as foreign and
attacks steadily with the intention of destroying them. The immune response is not
exclusively targeted to the foreign substance, but has a wider action that leads to the
destruction of the whole intruder.
Nonetheless, how can the immune system avoid attacking the body itself? Recalling
a study of the Pennsylvania School of Medicine (Olenchock et al. 2006), small fatty
acids called diacylglycerols (DAGs), and the enzymes that metabolize them, are crit-
ical players in the molecular pathway that leads to activation of the immune system.
In fact, understanding under which conditions the immune cells get activated is cru-
cial to fight either cancer, or autoimmune diseases, or moreover organ transplant re-
jection. They found out that when DAGs are chemically modified by enzymes called
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diacylglycerol kinases (DGKs), T cells become unresponsive to foreign substances and
to self-environment. The discovery was made by studying mice that had been engi-
neered to lack DGKs. When DAGs could not be chemically altered because the DGKs
were absent, the T cells were hyperreactive to foreign antigens and could not be made
tolerant to host cells.
This preamble leads to the fact that, potentially, the immune system has the ability
to target and therefore destroy cancer cells (Pardoll 1999). Clearly there are limits on
the immune system’s ability to fight cancer on its own, otherwise immunotherapy
would have no matter of existance. Sometimes the immune system cannot detect the
cancer cells as foreign because the difference between them and normal cells is not
so striking. Sometimes the immune system is even able to recognize the cancer cells,
but the response might not be strong enough to get rid of the invasion. Cancer cells
themselves could as well contribute giving off substances that inhibit the immune
system response.
Accordingly, the premise that has led to the development of cancer immunotherapy
is that the immune system owns the instruments to fight cancer, but it needs a push.
As it was mentioned above, the main characters in this action are T-cells: they have
receptors on their surface acting as gas pedals or brakes of activation and inhibition.
There are three types of cancer immunotherapy:
• Monoclonal antibodies, useful in treating cancer because they can be designed
to attack a very specific part of a cancer cell;
• Immune checkpoint inhibitors, which block the ability of certain proteins, called
immune checkpoint proteins, to limit the strength and duration of immune re-
sponses; researchers learnt that tumors can pilot these proteins and use them
to suppress immune responses, so blocking the activity of immune checkpoint
proteins releases the brakes on the immune system, increasing its ability to de-
stroy cancer cells (Pardoll 2012);
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• Cancer vaccines, substances put into the body to start an immune response
against certain diseases, for example helping prevent or treat cancer.
Especially drugs that act as checkpoint inhibitors have been recently approved by the
Food and Drug Administration (FDA), as ipilimumab for receptor CTLA-4 (with im-
portant results, see Prieto et al. 2012) and nivolumab or pembrolizumab for receptor
PD-1 (Ansell et al. 2015). These treatments concentrate on one side of the immunity,
called adaptive, which is meant to provide a durable response relying on the memory
capacity: this immune action, once elicited, remembers the intruder and performs a
continuous filter.
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1.2 T-cell subtypes
The importance of lymphocytes has already been outlined in relation to the immune
system. Memory T cells constitute the most abundant lymphocyte population in the
body for the majority of a person’s lifetime; however, our knowledge of memory T
cells derives mostly from mouse studies. Mice have a short lifespan, which cannot
sum up the wider exposure to pathogens that occurs inexorably over many decades
in humans. Thus, it is important to focus on human studies with human data.
In the human body, after the encounter with a specific antigen, which is a molecule
capable of inducing an immune response (production of an antibody), the immune
response outbreaks, leading the single naïve T cell to the development of multiple
subsets of memory T cells. Each subset has different and personal properties and
expression profiles. Due to heterogeneity of the memory T cell compartment, a clas-
sification is required to identify the various subsets based on phenotypic traits and
properties.
According to Golubovskaya and Wu 2016, T cells express TCR (T cell receptor) and can
express either CD8 glycoprotein on their surface, therefore being called CD8+ T cells
(cytotoxic), or CD4 glycoprotein, being accordingly called CD4 cells (helper T cells, or
Th). CD4+ cells differentiate into different subsets: Th1, Th2, Th9, Th17, Th22, Treg
(regulatory T cells), and Tfh (follicular helper T cells). These different CD4+ subsets
play a critical role in the immune and effector response functions of T cells.
The mechanisms of subdivision into subsets is similar comparing CD4+ and CD8+
T cells, thus our intention is to focus selectively on CD8+ T cells due to their cyto-
toxicity, that is the quality of inducing cell death, and therefore their relevance to the
immunotherapy application. The epitope, the part of the antigen recognized by the
immune system, elicits the response of the thymus, which releases mature naïve T
cells (TN). TN cells are the starters of the immune response after the encounter with
an antigen. They are in a quiescent and non-dividing state and are easily recognized
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because of the over-expression of the lymph-node homing receptor CD62L and lack
of the most common activation markers (HLA-DR, CD69). The TN, due to antigen
encounter, are stimulated to proliferation as effector cells. According to Obar and
Lefrançois 2010, 95% of them have a short life, since they are terminally differentiated
effector cells and die by apoptosis, being still able of immediate cyto-toxicity ex vivo;
the other 5% is constituted by memory precursor effector cells, which are bound to
form the memory T-cell population. This last type is recognized by the expression of
CD27 (member of the tumor necrosis factor family) and is characterized by a lack in
the immediate killing activity.
The different subsets of memory T cells are detected via exploitation of specific mark-
ers, like CCR7, a mediator of the homing to the lymph-nodes (LNs). CCR7 expression
is related to a lack of production of IL-4, IL-5 effector cytokines and leads to a potential
homing to secondary lymphoid tissues, whereas the CCR7- counterpart has opposite
production outcomes and the ability to move to perypheral lymphoid tissues. The
cells that express this mediator are defined as central memory (TCM), the ones that
don’t express it are called effector memory (TEM). A distinguishable phenotypical dif-
ference between these two memory types is the fact that TCM have longer telomeres
compared to TEM, probably due to a faster replication cycle of the latter one.
Between the TN and the TCM, the stem cell memory cells (TSCM) have been identi-
fied: they have stem-cell like properties, retaining a largely naïve phenotype, but also
showing high expression of CD95 antigen, which is characteristic for all memory cells.
They preserve genes typical of the naïve with the same functional capacity of memory
cells and are also able to self-renew in vitro: the capacity of maintaining the original
phenotype after differentiation induction has been demonstrated to be higher with
respect to TCM (Gattinoni et al. 2011). Another important property is an enhanced
multipotency, as they are able to generate all the memory subsets, whereas it is not
possible for them to be generated by other memory subtypes. Additionally, this type
is characterized by a superior survival potential.
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FIGURE 1.1: The main features of T cell subsets are summed up in
terms of markers (on/off switch) and likely evolution from naïve (se-
quence and marker features extracted from Mahnke et al. 2013).
It has been made clear that the quickest way to discriminate between different cell
types is offered by the expression of specific markers in different combinations. Given
that the expression of a marker is binary (on/off), four markers have been selected as
fundamental signals of expression to differentiate the subsets: CD45RO, CCR7, CD28
and CD95 (Mahnke et al. 2013).
Besides the already presented model in which effector cells are the ancestors of cen-
tral and effector memory, the following (Figure 1.2) has been proposed by Farber, Yu-
danin, and Restifo 2014. All the memory subsets descend directly from the naïve and
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the final stage is the irreversible compartment of TEff that leads quickly to apopto-
sis (however it is still unclear, and therefore possibile, whether TEff and TEM have a
reversible link). The markers involved in this alternative scheme have not changed
from the ones represented in Figure 1.1. However, the situation is fluid, since numer-
ous paths are being followed, that could potentially amplify our knowledge on the
topic: a brief example can be the examination of the differentiation of memory cells
after multiple antigenic encounters.
FIGURE 1.2: Graphical illustration of an alternative model for devel-
opment of T cell subsets from a naïve T cell (Farber, Yudanin, and
Restifo 2014).
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1.3 Why quantifying the immune contexture
The following subsection is a step towards the understanding of the relationship be-
tween tumor and the immune landscape in humans. The main accepted ascertain-
ment is that tumors grow developing an elaborate network of cells, vessels and re-
leasing signaling molecules such as cytokines and chemokines; besides this, it can
be infiltrated by immune cells. It is worth concentrating on this last mixture in the
cancer contexture, because different combinations of infiltrating immune cells lead
to different effects on clinical prognosis.
To give a hint about the variability of these possible combinations, in the tumor all im-
mune cells can be present, like macrophages, mast cells, dendritic cells, natural killer
(NK) cells, B cells, naïve, memory lymphocytes and whatever T cell subset. The vari-
ability and the variations are triggered by inflammatory factors (Fernández-Figueras
et al. 2007) and, as well, different regulatory T cells (Treg) subpopulations seem to
explain discrepancies among various types of tumor (Conrad et al. 2012). Moreover,
the immune cells can be situated in different locations, either in the core, in the inva-
sive margin or in the adjacent tertiary lymphoid structures (TLS), ectopic lymphoid
formations found in inflamed, infected, or tumoral tissues exhibiting all the charac-
teristics of structures in the lymph nodes (LN) associated with the generation of an
adaptive immune response (Dieu-Nosjean et al. 2014): a correlation has been found
between high densities of TLS and prolonged patient’s survival in more than 10 dif-
ferent types of cancer (Sautès-Fridman et al. 2016).
For instance, CD8+ T cells can be visible in both the invasive margin and the core
of the tumor, while the TLS seem to lack these cells. In addition, the mixture of im-
mune cells can vary differently in relation to tumor types. Some components of the
immune contexture, more than others, are helpful in terms of good prognosis: this
fact is shared by multiple papers, such as Dave et al. 2004, which paved the way in
the early years of the XXI century, while in Parker et al. 2008 and Parker et al. 2009
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the importance of the subtypes’ population was outlined. In general, the correla-
tion between infiltration of the cancer contexture by immune cells and the clinical
outcome has been researched in various tumor types and a strong lymphocytic infil-
tration (TILs) has always been stated as beneficial for the patient medical condition.
According to Fridman et al. 2012, the infiltration of especially CD3+ T cells, CD8+ T
cells and CD45RO+ memory T cells is associated with a longer disease-free survival
after therapy. Surprisingly, as stated by Hadrup, Donia, and Straten 2013, as little as
approximately 30% of the cells in the tumor are represented by pure cancerous cells:
this implies that tumor cells are not able to survive alone, but need a guest environ-
ment to grow. This assumption is shared among the scientific community, leading to
a massive production of papers on the topic: Afanasiev et al. 2013 was one of the first
to propose the therapeutic mobilization of anti-cancer T cells. Indeed, the previously
stated variability in the tumor landscape is a considerable obstacle which needs to
be taken into account. The approach followed in this dissertation will focus on two
complementary paths: on one hand, RNA-Sequencing (RNA-Seq) data processing, on
the other, immunohistochemistry (IHC) imaging analysis (developed firstly by Galon
et al. 2012), both meant to estimate the numerosity of CD8+ T cell subtypes in the
cancer contexture.
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1.4 RNA sequencing
RNA-Sequencing (RNA-Seq) is a technique useful to study the transcriptome, which
is the full range of messenger RNA, or mRNA, molecules expressed by an organism.
The particular importance of this has to be found in the difference with the genome.
In fact, in contrast with it, that is characterized by relative stability, the transcrip-
tome changes, varying due to the different conditions of the organism. Technically,
the starting RNA is sequenced in random positions and the subsequently produced
reads, which are fractionary copies of the native RNA, are amplified and mapped on
a reference genome in the corresponding position (alignment): the number of reads
abundance (so called counts) mapping within a particular gene is proportional to its
mRNA (process schematized in Figure 1.3).
Indeed, for large transcriptomes, alignment is more complicated by the fact that a
wider section of sequence reads match multiple locations in the genome. One solu-
tion is to assign these multi-matched reads by proportionally assigning them based
on the number of reads mapped to their neighbouring unique sequences. Alterna-
tively, a paired-end sequencing strategy, in which short sequences are determined
from both ends of a DNA fragment, extends the mapped fragment length (Wang, Ger-
stein, and Snyder 2009).
Despite these obstacles, RNA-Seq has the advantages to become, and is indeed devel-
oping, as the gold standard for transcriptome analysis: in fact, this tool
• offers a sensitive and accurate measurement of gene expression;
• is not biased by a priori knowledge;
• can be applied to any species;
• is less expensive compared to other techniques (microarray is still more advan-
tageous under these terms, but the costs of RNA-Seq are rapidly decreasing over
the years).
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FIGURE 1.3: A typical RNA-Seq experiment. Long native RNAs are
first converted into a library of cDNA fragments. Sequencing adap-
tors are subsequently added to each cDNA fragment and a short se-
quence is obtained from each cDNA using high-throughput sequenc-
ing technology. The resulting sequence reads are aligned with the ref-
erence genome or transcriptome. The expression profile is therefore
calculated.
Progress has been brought on in areas including the definition of sense and antisense
transcripts, alternative splicing events, fused transcripts and transcription initiation
sites in physiologically normal and disease settings (Ozsolak and Milos 2010). There
exists a wide range of RNA-Seq methods, such as mRNA, targeted RNA Exome Capture
or total RNA, leading to a broad variety of possibilities in terms of studies. In fact, the
transcriptomes of stem cells and cancer cells are of particular interest to researchers
who try to understand the processes of cellular differentiation and carcinogenesis.
The readable information that certain genes encode in a precise moment, and un-
der a precise condition, can reveal the status of the cell. Therefore, a sick cell can
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unveil pathologic mechanisms of the disorder itself and the determination of genes
of importance (signature genes, see Chapter 3) sets control or alarm markers for de-
tection and cure of the disease. RNA-Seq comprises gene expression across all cell
types in the tumor, including immune cells: tumor data offer the possibility to inves-
tigate infiltrating immune cells, as well. Nonetheless, the count output produced by
such a method is far from being self-explanatory: data interpretation needs a prede-
termined pipeline, suitable for the challenges to face in a certain type of analysis. The
main usual steps comprise read mapping, counts computation, counts normaliza-
tion and differential expression (DE) testing (Finotello and Di Camillo 2015). In the
experimental section of this thesis (Chapters 3 and 4), some of these issues are going




Immunohistochemistry (IHC) is an oncology screening technique that allows to anal-
yse cells or tissue specimens collected from patients in early or advanced cancer stage
of progression. This technique has the aim to identify the identity of tumoral cells to
plan a clinical path of cure. Moreover, IHC is used as well to understand the dis-
tribution and localization of biomarkers and differentially expressed proteins, also in
non-cancerous patients. Technically speaking, the procedure involves two alternative
approaches, direct and indirect. The first one exploits the antibody action targeted to
the molecule that is object of research: the antibody itself is binded to a coloured
particle that highlights the target molecule when the complex between them is acti-
vated. The latter approach is similar, but instead uses a secondary antibody that is
targeted to the main antibody and carries the coloured particle. Recently, the sec-
ondary antibody has been substituted by conjugate polymers (e.g. dextran). IHC is
an alternative to immunofluorescency. Analysing images of the cancer immune con-
texture can be a powerful instrument both in cancer prevention and prognosis. This
has been already stated in the previous subsection (Fridman et al. 2012) in general
terms. Immune-based therapies have taken over the past ten years, but many pa-
tients fail to respond to these treatments because of the development of a generalized
resistance to them. Besides, tumors showing low mutational loads present insuffi-
cient reaction rates. Therefore, personalized cancer landscape analysis results vital in
terms of understanding the obstacles of immune therapy through identification of in
situ or circulating biomarkers.
According to Tsujikawa et al. 2017, response to therapy correlates with degree of in-
filtrated cell density in tumor contexture and, especially, with percentages of CD8+
T cells expressing the already mentioned markers. To validate this, the team led by
Tsujikawa exploited an IHC approach, using either biopsy or surgically resected spec-
imens in formalin-fixed paraffin-embedded tissue sections.
In the experimental section, a collection of all these premises will be translated into a
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FIGURE 1.4: Example of digital scan representing bright field sequen-
tial IHC of one formalin-fixed paraffin embedded (FFPE) section of
human cell carcinoma tissue.
pipeline to quantify the tumor contexture population of infiltrating immune cells. An
important ally, common to the study mentioned a few lines above, will be Cellprofiler
(Carpenter et al. 2006) software.
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1.6 Types of tumor samples
Despite being not strictly related to the quantification problem, it is worth recalling
the dualism between two main storing methodologies of cancerous tissue specimens,
Fresh Frozen (FF) and Formalin-Fixed Paraffin-Embedded (FFPE).
As reviewed by Lüder Ripoli et al. 2016, FF tissues are the best option in terms of
molecular analysis by gene expression measurements since their RNA is well pre-
served. However, these samples are not so abundant and their collection is mainly
restricted to tissue banks and research groups. On the other side, FFPE tissues repre-
sent a unique source of archived biological material (Von Ahlfen et al. 2007). The ad-
vantages of strategies based on the FFPE approach are sundry such as easy handling,
long-term cheap storage and suitability for immunohistochemical analyses. How-
ever, the RNA of FFPE specimens is of much lower quality than RNA obtained from FF
samples (see Scicchitano et al. 2006, study on microarray). According to Sengüven et
al. 2014, the chemical reactions induced by formalin are well known: the most impor-
tant molecular change is the formation of cross-links between proteins or between
proteins and nucleic acids, which make the eventual extracted RNA corrupted, or at
least not identical to the original one.
The quantification algorithm we are going to introduce will be tested on data com-
ing from both stored tissue examples for two reasons: confirming the robustness of
the algorithm itself and, on the sidelines, assessing the feasibility of a FFPE storage
instead of the FF one, for the beneficial reasons explained above.
The identification of genomic alterations based on the characterization of more than
500 GBMs has paved the way to understanding several novel mutated genes as well
as complex rearrangements of signature receptors: these discoveries lead to new di-
agnostic and therapeutic target candidates to focus on (Brennan et al. 2013) in the act
of analysing the feasibility of FFPE data exploitation, especially after the revelation of
an automated protocol for the nucleic acid extraction by Hennig et al. 2010, even if it
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was firstly assessed for breast cancer.
Many other studies previously faced the matter, with two-sided results: as in this re-
port, also in Penland et al. 2007, data suggest that meaningful RNA expression anal-
ysis can be performed on FFPE samples, with the warnings that many samples are
too degraded for analysis and that there is loss of information using FFPE-derived
compared to analysis of frozen samples; nonetheless, criteria to predict which blocks
will provide informative hybridizations were identified, with a consequent ready-to-
action application: the use of microarray expression profiling on FFPE samples to
identify tissue of origin in carcinoma of unknown primary (CUP), which represents
approximately 3% of all new cancer diagnoses.
1.6.1 Success in RNA Extraction from FFPE Tissue Specimens
Formalin-Fixed Paraffin-Embedded tissue samples have become a standard technique
to store and subsequently examine tumour specimens as it is cost effective and per-
fect to preserve morphology. However, it is also well known that formalin has a strong
chemical power and it can modify the composition of the nucleic acids, especially
RNA: therefore, the quality and the quantity of RNA extracted from FFPE tissues could
be lower than the expectations. One attempt was to replace formalin with other types
of fixatives, including Bouin’s solution, acetone or alcohol: the differences using these
protocols seem not to be consistent. The main steps forward came from the analy-
sis of the factors that could interfere with the amplification of genes from the sam-
ples (Gouveia et al. 2014): low amplification rate was hypothesized as related to the
presence of contaminants that inhibit the PCR main stages; the addition of a simple
washing step after sample rehydration improved the general quality of the data subse-
quently obtained. Moreover, the introduction of the washing step is likely to increase
the pH of the solution, assessing the value between 6.5 and 9.0, ideal for the efficiency
of the entire process (Scorsato and Telles 2011).
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1.6.2 RNA-Seq of FFPE tumor samples
One of the main issues that need to be investigated regarding FFPE RNA extraction
is the action of paraffin, allegedly responsible for fragmentation, cross-linking and
chemical modification of FFPE tissue-derived nucleic acids: though, new advances
in NGS technologies suggest optimistic perspectives on the investigation of genomes
and transcriptomes with limited sample material, situation ideally applicable to usu-
ally fragmented nucleic acids extracted from FFPE specimens. An important refer-
ence towards this direction is given by the study of Hedegaard et al. 2014, in which
the purpose was to determine the effects of formalin fixation, extraction method,
storage duration, tissue type, and tumour status on DNA and RNA NGS results using
formalin-fixed paraffin-embedded (FFPE) and frozen (FF) specimens. They were able
to identify strong correlations between the expression profiles in RNA-Seq data and
detect some variants in DNA extracted from exomes for the FFPE/FF couples. Never-
theless, the DNA Exome-Seq library preparation was successful for only ten samples
and eight variants out of 61 total specimens (29.5% of success), due to non-efficient
amplification of the product during PCR and gene modifications allegedly caused by
the chemical fixation: since the main kind of deamination was offered by cytosine to
uracil, the idea of using a different uracil tolerant DNA polymerase was also tried, with
no significant advantages. In total contrast to the issues encountered during FFPE-
derived DNA extraction, the library preparation from RNA-Seq data gave complete
satisfaction, offering 100% success rate, including samples collected two decades pre-
viously. Moreover, FFPE DNA generated a lower percentage of mapped reads, more
unaligned ends, more non-perfectly aligned reads, and more transition errors than
FF specimens. For FFPE RNA, still a higher percentage of non-perfect matches and a
lower percentage of total exon mapping were observed than with the FF specimens,
but the percentage of non-mapped reads was comparable. While the expression data
between matched FFPE and FF specimens was strongly correlated, 1494 genes were
found to be differentially expressed between FF and FFPE specimens in all analysed
18 Chapter 1. Introduction
tissue types.
1.6.3 Case study: RNA-Seq from FFPE and FF glioblastoma tumor samples
FIGURE 1.5: List of FF and FFPE samples selected based on Esteve-
Codina et al. 2017.
By calculating the paired-end distances for each experiment it is possible to evalu-
ate if the length of the RNA molecules is somehow affected by the storage technique:
FFPE samples revealed smaller distances between read pairs than FF counterparts.
Another important parameter, useful, once defined, to neutralize in vitro RNA degra-
dation effect and improve differential gene expression analysis is the TIN (transcript
integrity number, statistics visible in Figure 1.5): the lowest RINs were found in FFPE
samples, in correspondence to higher values of GC content, assessing a major RNA
degradation for these ones, but, while the values for FFs were homogeneous, the vari-
ability was more pronounced in FFPEs. Continuously focusing on variability, another
study from Gravendeel et al. (2012) ascertained that, selecting the most variable sets
on FFPE expression profiles, the degree of correlation improved dramatically, yielding
to an increased success rate (87%) in the assignation of the FFPE samples to cancer
subtypes precedently built on FF RNA-Seq data.
FFPE samples offered a higher number of duplicates than the FF counterpart and,
consequently, a lower quantity of uniquely mapped reads, especially in the most de-
graded samples; moreover, these ones presented also the fewer genes to consume
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25% of the reads: therefore, basically, the less intact libraries are strongly related to
a small number of dominant genes and the libraries themselves present less hetero-
geneity.
The correlation within each pair was substantially high (around 0.9), with only one
exception presented by the most degraded FFPE sample (correlation around 0.3).
So, it is easy to presume that FF and FFPE hide high similarities in gene expression.
Although a high correlation between FFPE and FF expression profiles has been de-
tected, it has also become clear that FFPE presented, more frequently than the FF
data, G to A and C to T transitions, due to the chemical action of paraffin during the
fixation process: in extreme cases, if the gene was partially degraded in FFPE data,





The division of Bioinformatics of the Medical University of Innsbruck (MUI) has re-
cently been seriously active in this direction and this is the place where the reported
analysis has been entirely conducted. Numerous studies have been reported on the
topic, leading to the introduction of the so-called immunophenoscore (Charoentong
et al. 2017), capable of identifying and summing up determinants of tumor immuno-
genicity into a scoring scheme that targets the cure path for a single patient. This
thesis is therefore inserted in a wider movement to develop a better understanding
on the consequences that the cell population implies in the cancerous tissue origin,
growth and maturation. For a catch up, it is worth citing Dander et al. 2014, Angelova
et al. 2015 and Hackl et al. 2016, that paved the way to this work.
The main concern of the experimental set-up, described in Chapter 3, is to integrate
the potential of RNA-Seq and imaging based quantification methods of the infiltrat-
ing lymphocytes in the tumor microenvironment, being associated with prognosis
(Fridman et al. 2012). Specifically, the focus on CD8+ T cell subsets is due to their
killing role, important for the mechanisms of immunotherapy.
The declared objectives of this thesis are enumerated below:
1. build a deconvolution algorithm from RNA-seq healthy human data, based on
SVR, which takes as input a mixture matrix, a signature matrix and a parameter
ν, and computes the relative T cell subtypes fractions (CM, EM, N);
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2. validate the deconvolution algorithm through healthy human data;
3. apply the deconvolution algorithm to tumor (glioblastoma) human data and
discuss the results;
4. test the immunoistochemistry-based pipeline (property of the Division of Bioin-
formatics, MUI) on IHC CD8+ stained images from cancerous patients and dis-
cuss the results.
To quickly overview the experimental set-up that we are switching to in the next Chap-
ter, the first section will focus on the quantification method as well as the core al-
gorithm CD8quant. The deconvolutional approach selected for the RNA-Seq side of
the study is going to be formulated based on human healthy donors data and subse-
quently furtherly tested on cancerous tissues in order to prove, on one hand, the ro-
bustness of the algorithm and, on the other hand, also its applicability to FFPE stored
tissues, that, as it has been previously acknowledged, are more durable in terms of
conservation, but potentially less reliable in terms of nature of the extracted data.
In conclusion, the imaging section will show a quantification pipeline, runCP.py, in-
tellectual property of the Medical University of Innsbruck (Division of Bioinformat-
ics), from IHC high resolution tissue tiles, applied to data consistent with the previ-
ous analysis in order to calculate the number of total CD8+ T cells. Unfortunately, due
to legal issues of divulgation, it has been not possible to give a complete view on the
entire topic, data and results, but what we presented is sufficient to be introduced to




3.1 Development of an algorithm for the quantification of CD8+
T cell sub-populations from tumor RNA-Seq data
3.1.1 Selection and preprocessing of RNA-seq data of CD8+ T cells subpop-
ulations
Since the aim of the project is to develop a computational method for the quantifi-
cation of the relative fractions of CD8+ T-cells subsets, the first step was to select
suitable publicly available RNA-seq data sets from enriched/purified Naïve CD8+ T
cells (N), effector memory CD8+ T cells (EM), and central memory CD8+ T cells (CM)
to reconstruct their expression signatures. We selected two studies, from Pulko et
al. 2016 (data available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE80306) and Bonnal et al. [referred to De Simone et al. 2016] (data available at
ftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR431/). Table 3.1 lists the considered
samples and summarizes the data characteristics. From now on, the data will be re-
ferred to as Pulko and Bonnal data sets.
Pulko data, available in SRA format, were converted into FASTQ format, with the
fastq-dump function of the SRA toolkit (https://trace.ncbi.nlm.nih.gov/Traces/
sra/sra.cgi?view=software).
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TABLE 3.1: Characteristics and information concerning the data of
Pulko and Bonnal datasets: GEO ID (https://www.ncbi.nlm.nih.
gov/geo/), cell type, markers used to isolate the cells, Pubmed ID.
GEO ID Cell Type Marker ID Pubmed study SE/PE
ERR431612 N CCR7+ CD45RA+ CD45RO- 26451251 Bonnal et al. PE
ERR431605 N CCR7+ CD45RA+ CD45RO- 26451251 Bonnal et al. PE
ERR431623 N CCR7+ CD45RA+ CD45RO- 26451251 Bonnal et al. PE
ERR431627 N CCR7+ CD45RA+ CD45RO- 26451251 Bonnal et al. PE
ERR431592 N CCR7+ CD45RA+ CD45RO- 26451251 Bonnal et al. PE
ERR431607 CM CCR7+ CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431578 CM CCR7+ CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431593 CM CCR7+ CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431602 CM CCR7+ CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431621 CM CCR7- CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431585 EM CCR7- CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431573 EM CCR7- CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431590 EM CCR7- CD45RA- CD45RO+ 26451251 Bonnal et al. PE
ERR431567 EM CCR7- CD45RA- CD45RO+ 26451251 Bonnal et al. PE
GSM2124048 EM CD45RA- CCR7- CD95+ CD28- 27270402 Pulko et al. SE
GSM2124049 EM CD45RA- CCR7- CD95+ CD28- 27270402 Pulko et al. SE
GSM2124050 EM CD45RA- CCR7- CD95+ CD28- 27270402 Pulko et al. SE
GSM2124051 EM CD45RA- CCR7- CD95+ CD28- 27270402 Pulko et al. SE
GSM2124052 EM CD45RA- CCR7- CD95+ CD28- 27270402 Pulko et al. SE
GSM2124053 N CD45RA+ CCR7+ CD95- CD28int 27270402 Pulko et al. SE
GSM2124054 N CD45RA+ CCR7+ CD95- CD28int 27270402 Pulko et al. SE
GSM2124055 N CD45RA+ CCR7+ CD95- CD28int 27270402 Pulko et al. SE
GSM2124056 N CD45RA+ CCR7+ CD95- CD28int 27270402 Pulko et al. SE
GSM2124060 CM CD45RA- CCR7+ CD95+ CD28+ 27270402 Pulko et al. SE
GSM2124061 CM CD45RA- CCR7+ CD95+ CD28+ 27270402 Pulko et al. SE
GSM2124062 CM CD45RA- CCR7+ CD95+ CD28+ 27270402 Pulko et al. SE
GSM2124063 CM CD45RA- CCR7+ CD95+ CD28+ 27270402 Pulko et al. SE
GSM2124064 CM CD45RA- CCR7+ CD95+ CD28+ 27270402 Pulko et al. SE
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3.1.2 Construction of the signature matrices for CD8+ T cell subpopula-
tions
We used the Bonnal data to derive the signature matrices for the CD8+ T cells subpop-
ulations of interest to be used in our deconvolution algorithm. Gene expression was
quantified from the FASTQ files using TIminer (Tappeiner et al. 2017). In particular,
the matrices of raw counts and transcripts per million (TPM) were constructed using
the executeKallistoDir function of TIminer. After quality control performed on the ex-
pression data, two samples of the Bonnal data set, ERR431585 and ERR431621, were
excluded from the subsequent analyses (see Results). To identify the signature genes
that are specific for the single CD8+ T cell sub-populations, we analysed the RNA-seq
counts with two R packages for differential expression analysis which assume a neg-
ative binomial (NB) distribution of the data: edgeR (Robinson, McCarthy, and Smyth
2010) and DESeq2 (Love, Huber, and Anders 2014). edgeR and DESeq2 provided lists
of differentially expressed genes with high overlap (data not shown), but the edgeR
analysis required a much lower computational time. Therefore, we selected edgeR
for the final selection of the signature genes. To identify the signature genes that are
specific for the CD8+ T cell sub-populations of interest and do not present high ex-
pression in other cell types, additional expression data were included for the follow-
ing cell types: B cells, dendritic cells, classically (M1) and alternatively (M2) activated
macrophages, monocytes, neutrophils, natural killer cells, regulatory T cells, CD4+ T
cells, and tumor cells. edgeR was applied to compare the libraries from the cell types
of interest with the others, using two different approaches. In the first approach (one
against all), the cell type of interest was compared with all the other libraries con-
sidered as a single group. In the second approach (one against each), the cell type
of interest was compared with each of the other cell types singularly. Before running
edgeR, the counts were pre-processed to filter out low expression genes: we kept only
the genes that presented a CPM-value (counts per million) higher than 2 in at least
three libraries. Given that the data were generated from purified/enriched cell types,
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edgeR was run imputing a constant value as dispersion of 0.01 (parameter required
by the package implementation). For each gene assessed in the comparisons, edgeR
computed the p-values and the log-fold-changes. In the one against each compari-
son, the minimum log-fold-change and the maximal p-value for each gene were con-
sidered. We selected as signature genes the genes that had a log-fold-change higher
than logfc and a p-value lower than pval (values presented below). Furthermore, to
improve the specificity of the selected signature genes, we considered an additional
heuristic: the average transcript per million (TPM) expression across all libraries in
the cell type of interest X i | i ∈ c must be K times higher than the maximum TPM ex-
pression selected among all other libraries X j | j ∉ c:
X i | i ∈ c ≥K ·X j | j ∉ c
with c being the cell type of interest. We tested different logfc and pval cut-offs and
different values for the K heuristic:
• pval = 0.0005, 0.001, 0.005, 0.01, 0.05, 0.10, 0.15, 0.20, 0.25;
• logfc = 0, 0.5, 1;
• K = 0.80, 0.85, 0.90, 0.95, 1.00, 1.05, 1.10, 1.15, 1.20, 1.25, 1.30.
Finally, for each set of signature genes, the corresponding signature matrix was built
taking the mean gene expression in TPM across all libraries belonging to each cell
type N, EM, or CM. In total, employing the one against all and the one against each
approach, 594 signature matrices (297 for each configuration, see the following Table
A.1) were built from the Bonnal RNA-seq data.
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3.1.3 Simulation of RNA-seq data from mixtures of CD8+ T cells subpopu-
lations
Pulko and Bonnal FASTQ data were used to generate 200 RNA-seq data sets from sim-
ulated mixtures of EM, CM, and N CD8+ subpopulations. The 100 data sets generated
from Pulko data consisted in 1 million single-end reads, whereas the 100 data sets
generated from Bonnal data consisted in 1 million read pairs. The CM, EM and N
cell proportions were simulated sampling, for each cell type, a uniform distribution
in [0,1] and then normalizing the fractions so to sum up to 1 (i.e. 100% in each simu-
lated mixture) (Table B.1).
To generate the read mixtures, Fc · R reads (or read pairs), were extracted from a single
FASTQ file of the Pulko or Bonnal study generated from the cell type c, where Fc is
the cell fraction for cell type c and R=1e6 is the number or total reads (or read pairs)
in the mixture. Reads from CM, EM and N were extracted from the original FASTQ
files with the Seqtk tool (Li 2012) and admixed in the final single-end or paired-end
FASTQ files. From each mixture FASTQ files, gene expression was quantified using
the executeKallistoDir function of TIminer to compute the matrices of raw counts and
TPM, analogously to what we have done for the signature matrices construction.
3.1.4 Implementation of the deconvolution algorithm
We implemented CD8quant, a deconvolution algorithm based on nu Support Vector
Regression (nu-SVR) similar to that of CIBERSORT (Newman et al. 2015) but intended
for the quantification of the relative cell proportions of three different CD8+ T cell
subpopulations. CD8quant takes as input a signature matrix describing the signa-
tures of the three CD8+ T cell types of interest, i.e. CM, EM, and N, and a mixture ma-
trix describing the expression of different cell mixtures and estimate through decon-
volution the relative fractions of the CD8+ sub-types. Both matrices must represent
gene expression in TPM. The deconvolution with nu-SVR can be run with different
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values of the nu parameter, which controls both an upper bound on training errors
and a lower bound on support vectors. Higher values of ν yield narrower ε-tubes and
consequently, more support vectors. Before performing deconvolution with nu-SVR,
CD8quant normalizes the signature matrix and the mixture matrix using the following
formula
M atr i xnorm = M atr i x−mean(M atr i x)
SD(M atr i x)
and are then filtered to keep only the genes in common. After deconvolution, possible
negative cell fractions estimated with nu-SVR are casted to zero and normalized so
that the final cell fractions to sum up to 1.
3.1.5 Identification of the optimal signature matrix and assessment of de-
convolution performance
CD8quant was applied to all the mixture matrices from Pulko data using each time
a different signature matrix (Table A.1) and using ν=0.5. Both the configurations,
one against each and one against all, were tested. The cell fractions estimated by
CD8quant where then compared with the true fractions (Table B.1) using Pearson’s
correlation and Root-mean-square error (RMSE).




i=1(x i− xˆ i)2
n
The values of RMSE and correlation were calculated considering both one single cell
type of interest at a time and all cell types together (overall statistics). Finally, the
signature matrix with the lowest overall RMSE was selected as basis signature for the
CD8quant algorithm (called CD8sig from now on). The CD8sig signature was the used
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to deconvolute the Pulko and Bonnal simulated mixtures varying the nu-parameter
value, selected as 0.25, 0.5 and 0.75.
3.1.6 Application of CD8quant to RNA-seq data from fresh frozen and formalin-
fixed paraffin-embedded data from human bulk tumors
In order to verify the applicability of CD8quant to cell mixtures from from fresh frozen
(FF) and formalin-fixed paraffin-embedded (FFPE) samples of human tumors, we
considered paired FF and FFPE samples from four glioblastoma tumors profiled with
RNA-seq available in the literature (Table 3.2). The data, that from now on will be re-
ferred to as the Codina dataset (Esteve-Codina et al. 2017), were downloaded at the
link https://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP089805.
Run ID Sample Name Age Sex Tissue SE/PE Tumor Type
SRR4241104 Case 1_FF_AA6360 55 female FF brain PE Glioblastoma
SRR4241105 Case 1_FFPE_AA6364 55 female FFPE brain PE Glioblastoma
SRR4241106 Case 2_FF_AA6361 51 female FF brain PE Glioblastoma
SRR4241107 Case 2_FFPE_AA6365 51 female FFPE brain PE Glioblastoma
SRR4241108 Case 3_FF_AA6362 79 male FF brain PE Glioblastoma
SRR4241109 Case 3_FFPE_AA6366 79 male FFPE brain PE Glioblastoma
SRR4241110 Case 4_FF_AA6363 53 female FF brain PE Glioblastoma
SRR4241111 Case 4_FFPE_AA6367 53 female FFPE brain PE Glioblastoma
TABLE 3.2: Characteristics of Esteve-Codina glioblastoma RNA-seq
data: library ID in the Sequence Read Archive, sample name, age
and sex of the patient, tissue type (FF=Fresh Frozen, FFPE=Formalin-
Fixed Paraffin-Embedded), and tumor type.
The Esteve-Codina FASTQ files were analysed with the executeKallistoDir function
of TIminer to extract gene counts and TPM, as explained above. The mixture matrix
of the gene TPM was then analysed with CD8quant, using the CD8sig signature and
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three different ν values (0.25, 0.5, 0.75), to estimate the fractions of EM, CM, and N
CD8+ T cells subtypes. The cell fractions from paired FF-FFPE (i.e. samples generated
from the same tumor) (Table 3.2) were compared considering RMSE and Pearson’s
correlation.
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3.2 Quantification of CD8+ T cells from tumor images
This experimental section comprises the cell quantification, with a focus on nuclei
of CD8 IHC (immunohistochemistry) stained images. The provenience and nature of
patients and their cancer images is intellectual property of the team involved in the
experiments, therefore this type of information cannot be divulgated. The pipeline,
meant to go through all the analysis steps, has been developed by Clemens Mayer,
under the supervision of Zlatko Trajanoski, head of the Bioinformatic department of
the Medical University of Innsbruck. This workflow utilises several public available
tools for the different steps of pre-processing (bftools, Linkert et al. 2010), classifi-
cation (Ilastik, Sommer et al. 2011) and segmentation (CellProfiler, Kamentsky et al.
2011) and combined the individual steps in a python script (runCP.py, available at the
link https://github.com/mui-icbi/IHCount), which is easy to use and to adapt.
3.2.1 Preprocessing
High resolution images were preprocessed by Mayer himself, who provided different
sets related to various patients. Each set was organized in a folder, containing the tiles
(2000x2000 pixels) the images have been cropped into. The tiles were converted from
∗.tiff to ∗.png.
3.2.2 Classification
The Pixel Classificator module of Ilastik was used to establish classifiers from a sub-
set of the previously generated image tiles. I manually selected a few images, which
represent the areas of interest on the tissue slide. Using manual annotation, that is ex-
ploiting the brush-like tool on Ilastik, the classifiers were trained to distinguish CD8+
cells (blue and brown round-shaped cells) and all nuclei (nuclei, only the darker cells)
on the selected IHC images, as well as tissue and background. The color protocol, for
convenience in the following quantification step, was decided in the beginning of the
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analysis and not changed throughout the whole pipeline: red (either positives or nu-
clei), blue (background) and green (tissue). As a result of running the classifier as
a batch process on all tiles of an image, I obtained two sets of so called probability
maps. One set shows the probabilities for positives and the second for nuclei on the
slide. These two image sets were used for the following segmentation and quantifica-
tion step.
3.2.3 Segmentation and Cell Quantification
The final phase of the analysis has been actuated in collaboration with Mayer: seg-
mentation and counting were performed with CellProfiler. This program presented
the possibility to reduce noise and to isolate the three different classes by multiple
intensity based operations, as good as possible: this optimization process was per-
formed by Mayer as preliminary step to the segmentation. The probability maps,
once obtained from Ilastik, were loaded into CellProfiler, exploiting one of the com-
mands present in the pipeline runCP.py in the python environment. This step could
also be manually performed through the CellProfiler’s GUI. The Bioinformatics team,
acknowledged above, created a pipeline (IHCount.cppipe4) that uses several internal
modules to identify and count positive stained cells, nuclei and the area of the tis-
sue. As a first step, the probability maps were split by the different colour channels
(red, blue, green) and converted into grayscale. In the end, the final output involved
tables for each image that list the questioned parameters for each single tile. The
combination of the results of each single tile offered a uniform macro-table with the




4.1 Validation of the Deconvolution Algorithm
4.1.1 Filtering of Bonnal’s data
All Bonnal RNA-seq libraries listed in Table 1 were used to generate the signature ma-
trices, with the exception of ERR431585 and ERR431621. The ERR431585 library was
discarded due to a very low expression of the CD8A and CD8B maker genes (Figure
4.1), whereas the ERR431621 library was discarded for its dissimilarity from the other
EM libraries revealed by principal component analysis (PCA) (Figure 4.2).
FIGURE 4.1: Barplots showing the low gene expression of CD8A and
CD8B in the library ERR431585, therefore excluded from the con-
ducted analysis, because of its irrelevance to the topic.
34 Chapter 4. Results and Discussion
FIGURE 4.2: PCA of the Bonnal dataset (ERR431585 already ex-
cluded). ERR431621 is represented by the black dot and it is clear
the non-belonging to the EM cluster.
4.1.2 Analysis of simulated data derived from the Pulko’s study
100 simulated mixtures were generated from all the Pulko libraries (Table 3.1) with
exception of the two libraries described in the previous section, and considering the
relative cell fractions reported in Table B.1.
The deconvolution results obtained with CD8quant on these data are presented for
both the configurations one against each and one against all. Table B.2 describes
the deconvolution performance obtained by CD8quant (ν=0.5) using the diffent the
Pulko mixtures.
We selected the signature matrix with the lowest overall RMSE, i.e. Sig_1vs1_103, as
basis signature for the CD8quant algorithm (CD8sig). The CD8sig signature was then
used in the deconvolution of the Pulko simulated mixtures with CD8quant, using
three values of the nu parameter: 0.25, 0.5, 0.75. The results are presented in Table
4.1 and Figure 4.3.
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RMSE all RMSE CM RMSE EM RMSE N corr all corr CM corr EM corr N
nu = 0.25 0.18 0.19 0.2 0.14 0.3 0.36 0.45 0.63
nu = 0.5 0.16 0.18 0.15 0.13 0.47 0.49 0.53 0.69
nu = 0.75 0.15 0.17 0.15 0.14 0.5 0.49 0.53 0.69
TABLE 4.1: Deconvolution performances obtained by CD8quant with
the CD8sig signature using different nu parameters. The columns
show the performance parameters expressed as RMSE and Pearson’s
correlation.
FIGURE 4.3: Deconvolution performances obtained by CD8quant
with the CD8sig signature using different ν parameters. The X-axis
presents the real concentrations for each simulation, while the Y-axis
represents the estimated values after the application of the algorithm.
The red line lays along the 45◦ diagonal.
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4.1.3 Analysis of simulated data derived from the Bonnal’s study
100 simulated mixtures were generated from the Bonnal libraries (Table 3.1) consid-
ering the relative cell fractions reported in Table B.1. To furtherly check the quality
of the selected signature, we deconvoluted the Bonnal simulated mixtures using the
CD8sig signature. On these data, a higher performance is obtained probably due to a
higher similarity of the Bonnal signature and mixture profiles.
FIGURE 4.4: CD8sig and the preferred ν set-up applied to Bonnal
mixture through CD8quant algorithm.
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4.1.4 Deconvolution of the tumor RNA-seq data from FF and FFPE samples
To test the applicability of CD8quant to both FF and FFPE data, we considered the
Esteve-Codina data set (see Chapter 3, Table 3.2) which consists in RNA-seq expres-
sion data form four pairs of FF-FFPE samples each taken from the same tumor. As it
is evident in Figure 4.5 and Table 4.2, gene expression has high correlation for all pairs
except for the Pair 2, due to the low quality of the FFPE sample for this pair (Esteve-
Codina et al. 2017).
FIGURE 4.5: Correlation plots of log2(CPM+1) Codina data. Each plot
is related to one single pair and shows the assessment of the data
along the 45 degrees line (red).
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correlation RMSE ID_FF ID_FFPE
Pair1 0.9356 0.8886 Pair1_FF_AA6360 Pair1_FFPE_AA6364
Pair2 0.6185 24.926 Pair2_FF_AA6361 Pair2_FFPE_AA6365
Pair3 0.9603 0.6797 Pair3_FF_AA6362 Pair3_FFPE_AA6366
Pair4 0.968 0.6315 Pair4_FF_AA6363 Pair4_FFPE_AA6367
TABLE 4.2: Correlation and RMSE within each pair, obtained com-
paring FF and FFPE samples’ gene expression from the same tumor.
FIGURE 4.6: Correlation plots of the bulk tumor deconvolution out-
put with Codina mixture matrix.
We analysed the Esteve-Codina dataset with CD8quant using the CD8sig and three
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values for ν parameter, that is 0.25, 0.5, 0.75. The best results are obtained with
ν=0.25. The high correlation between the FF and FFPE results confirms the robust-
ness of CD8quant in the analysis of possibly degraded FFPE samples, as in the case of
Pair2.
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4.2 Quantification of CD8+ cells from IHC tumor images
The images for each patient were digitally cropped into squared subsets of 2000x2000
pixels of dimension. Figure 4.7 shows an example of full image (left) after the appli-
cation of the cropping net, while in the same Figure on the right, a subset image is
presented.
FIGURE 4.7: On the left, the full image, on the right an already
cropped image extracted from the left one.
The following training of the pixel classifier was executed manually, exploiting a colour
brush-like procedure provided by Ilastik itself. The process of training was 100% man-
ual, sharing the strength and the weaknesses of the human eye: in Figure 4.8 it is
possible to observe how a partially brushed tile looks like after a few steps into the
training.
Figure 4.9, instead, presents a probability map, produced by the pixel classifier mod-
ule, after the manual training. As mentioned above, the ability of human eye is not
capable of achieving a perfect result, therefore we exploited a CellProfiler’s feature
to reduce the noise: especially in the background (blue), the green presence was re-
duced and the round-like shape of nuclei and positives (red) was enhanced (Figure
4.2. Quantification of CD8+ cells from IHC tumor images 41
FIGURE 4.8: Example of training, positives session: the vivid colours
(blue, red and green) have been traced by the paint brush manually,
while the soft-faded coloured foil over the tile is due to the activation
of the "live checking" feature.
4.9, right) to enable a better segmentation and object detection.
FIGURE 4.9: Classified tile before optimization VS Classified tile after
optimization.
CellProfiler produced an imaging output that involves segmentation results for nu-
clei and positives, as well as images of the tissue area (Figure 4.10, background not
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shown). The subsequent output was instead a table (Table 4.3) resuming the IDs of
patients (obscured for privacy reasons) and the cell count for the images to each of
them related: only the CD8 results are shown in this section for consistency to main
topic.
FIGURE 4.10: Segmentation output of CellProfiler regarding tissue












Patient 01 1.94E+08 191155 17823 9.323847
Patient 02 4.47E+08 1085883 200424 18.45724
Patient 03 1.9E+08 96719 6901 7.135103
Patient 04 51387976 62796 7874 12.53902
Patient 05 7.98E+08 1094620 75971 6.940399
Patient 06 5.01E+08 1331952 75937 5.701181
Patient 07 5.83E+08 1316218 133625 10.15219
Patient 08 1.9E+09 1499273 85280 5.68809
Patient 09 1.42E+09 1462025 81232 5.556129
Patient 10 1.65E+09 822383 126197 15.34528
Patient 11 8.68E+08 1445921 303031 20.95765
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Patient 12 1.49E+09 1560646 88535 5.672971
Patient 13 1.23E+09 2264420 43349 1.914353
Patient 14 4.27E+08 878257 43698 4.975537
Patient 15 1.82E+09 1322095 69681 5.270499
Patient 16 60110177 88409 7217 8.163196
Patient 17 9.76E+08 1472746 114593 7.780907
Patient 18 1.32E+09 1425728 95948 6.729755
Patient 19 6.7E+08 919512 133490 14.51748
Patient 20 1.26E+08 142645 6842 4.796523
Patient 21 6.01E+08 1286295 55883 4.344493
Patient 22 1.23E+08 225973 5241 2.319304
Patient 23 1.52E+09 2382471 286175 12.01169
Patient 24 1.45E+09 1373325 54197 3.946407
Patient 25 9.46E+08 2219886 173755 7.827204
Patient 26 1.06E+09 2097571 79708 3.800014
Patient 27 1.14E+08 278083 4446 1.598803
Patient 28 8.94E+08 536626 69129 12.88216
Patient 29 1.24E+08 274285 6909 2.518913





The tumor immune contexture, defined as the type and density of tumor-infiltrating
immune cells, has a strong impact on patients’ prognosis and response to therapy.
In particular, high infiltration of cytotoxic CD8+ T cells, which has the capability of
recognize and kill tumor cells, has been associated with a good prognosis. Thus, the
quantification of CD8+ T cells is of paramount importance for the stratification of
cancer patients and for the development of effective combination therapies.
In this thesis, we developed two computational approaches for the quantification
of CD8+ T cells and their subtypes. First, we developed a deconvolution algorithm,
CD8quant, which quantifies the relative cell fractions of naïve, central memory, and
effector memory CD8+ T cells from bulk tumor RNA sequencing (RNA-seq) data. Sec-
ond, we optimized a bioinformatics pipeline for the for the quantification of total
CD8+ T cells from immunohistochemistry (IHC) images of tissue slides derived from
formalin-fixed paraffin-embedded (FFPE) samples.
As we already acknowledged, RNA-Seq data are difficult to handle and process due to
their complexity. Therefore, in the deconvolutional section (Chapter 4, page 33), the
necessity of a careful preprocessing was made clear: the quality of the results we pro-
posed strikingly improved after the detection and filtering of libraries that seemed not
suitable for the analysis we were trying to carry on. For example, in a study that fo-
cuses on CD8+ T cells, we could only accept samples with at least high levels of CD8A
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and CD8B gene expression. Once reassured about the quality of the data, the atten-
tion switched to the extraction of the genes that could represent the different T cell
subsets of interest (CM, EM, N), the so-called signature genes, searched by process-
ing processing data of healthy humans. The real challenge was to detect an universal
gene set, applicable to every patient, healthy or not. The entire process has been com-
putationally demanding, but the aim of a robust signature gene matrix could only be
pursued through the testing of a high number (almost 600, see A.1 with candidates
and B.2 with results) of different candidates on a different, but comparable dataset.
CD8quant, validated on 200 simulated RNA-seq data sets, obtained high deconvolu-
tion performance.
Besides this, a parallel aspect that is worth to outline is referred to the feasibility of
the comparison between FF and FFPE stored data; the results obtained primarly in
Esteve-Codina et al. 2017 and then confirmed by our analysis suggest that, under
certain conditions, it is definitely possible to substitute the FF technique with the
handier FFPE one. Surely, the initial check on the quality of the samples is a manda-
tory habit to avoid unprocessable and therefore misleading data. In fact, the one we
solely referred to as Pair 2 has been immediately detected as poorely qualitative. The
decision not to exclude it from the analysis but to persevere in trying to process it
was intentionally made to highlight the difficulties that can be encountered without
a proper preprocessing.
What confirmed the robustness of the algorithm CD8quant and the CD8sig has been
the application of the algorithm itself on the Codina dataset: testing a signature ma-
trix, extracted from healthy donors, on data belonging to cancerous (glioblastoma)
donors, was the real challenge. The results seem absolutely encouraging for two rea-
sons: the feasibility of the comparison between FF and FFPE data is confirmed and
the quality and strength of the pair algorithm-signature is established by a further
proof.
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Given the availability of large collections of FFPE tumor samples exploited for im-
age pathology, and now also for RNA-seq, these methods represent valuable tools for
the efficient extraction of immunological features from tumor data and may provide
mechanistic insights for the optimization of anti-cancer treatments.
Concerning the imaging section, despite, as we already recalled, the possibilities of di-
vulgation of precise information on the data are strongly reduced by legal restrictions,
the project revealed itself as a convincing complementary approach in the quantifica-
tion of cell subsets in the cancerous contexture. The pipeline is not easily accessible to
a simple clinician, whose competences are definitely far from the informatic bound-
aries. However, for whom is qualified enough to handle it, the quantification tool will
be available and free to adapt. In fact, besides the precision of the counting, one of
the strengths of the pipeline is the possibility to intervene and modify according to
necessities, as well as exploit only one sub-tool at a time, regardless of the original
flow.
Future work will focus on the integration of the strengths of these two approaches:
the image results (i.e. absolute cell counts on total CD8+ T cells) will be used to scale
the deconvolution results (i.e. relative cell fractions, but available for more cell types)
and obtain an absolute quantification of naïve, effector memory and central memory
CD8+ T cells infiltrating human tumors. The hope is that the ambivalent aim of this
thesis has been reached: summing up the state of the art in the bioinformatic tools
related to cancer immunology and, simultaneously, approaching an integration at-
tempt of two of the most promising methodologies, RNA-Sequencing and IHC imag-
ing. At the moment, the particular kind of data used in the experimental section is not
easy to retrieve online, firstly because human-bound studies are still less popular than
mice experiments, secondarily because the consent to share sensitive data on delicate
diseases, like cancer, is complicated to obtain. Ideally, it is desirable a global effort on
the production of data, especially CD8+ which, as seen in Chapter 1, are strongly re-
lated to cancer patients prognosis. More data implies more effort in the topic, and
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therefore achieving a shared consensus, that will be exceptionally relevant in the run
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Materials and Methods - Appendix
A.1 Signature gene matrix - Candidates’ characterization
Signature ID pval K logfc
Sig_1vs1_001 5,00E-04 0.8 0
Sig_1vs1_002 5,00E-04 0.85 0
Sig_1vs1_003 5,00E-04 0.9 0
Sig_1vs1_004 5,00E-04 0.95 0
Sig_1vs1_005 5,00E-04 1 0
Sig_1vs1_006 5,00E-04 1.05 0
Sig_1vs1_007 5,00E-04 1.1 0
Sig_1vs1_008 5,00E-04 1.15 0
Sig_1vs1_009 5,00E-04 1.2 0
Sig_1vs1_010 5,00E-04 1.25 0
Sig_1vs1_011 5,00E-04 1.3 0
Sig_1vs1_012 5,00E-04 0.8 0.5
Sig_1vs1_013 5,00E-04 0.85 0.5
Sig_1vs1_014 5,00E-04 0.9 0.5
Sig_1vs1_015 5,00E-04 0.95 0.5
Sig_1vs1_016 5,00E-04 1 0.5
Sig_1vs1_017 5,00E-04 1.05 0.5
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Sig_1vs1_018 5,00E-04 1.1 0.5
Sig_1vs1_019 5,00E-04 1.15 0.5
Sig_1vs1_020 5,00E-04 1.2 0.5
Sig_1vs1_021 5,00E-04 1.25 0.5
Sig_1vs1_022 5,00E-04 1.3 0.5
Sig_1vs1_023 5,00E-04 0.8 1
Sig_1vs1_024 5,00E-04 0.85 1
Sig_1vs1_025 5,00E-04 0.9 1
Sig_1vs1_026 5,00E-04 0.95 1
Sig_1vs1_027 5,00E-04 1 1
Sig_1vs1_028 5,00E-04 1.05 1
Sig_1vs1_029 5,00E-04 1.1 1
Sig_1vs1_030 5,00E-04 1.15 1
Sig_1vs1_031 5,00E-04 1.2 1
Sig_1vs1_032 5,00E-04 1.25 1
Sig_1vs1_033 5,00E-04 1.3 1
Sig_1vs1_034 0.001 0.8 0
Sig_1vs1_035 0.001 0.85 0
Sig_1vs1_036 0.001 0.9 0
Sig_1vs1_037 0.001 0.95 0
Sig_1vs1_038 0.001 1 0
Sig_1vs1_039 0.001 1.05 0
Sig_1vs1_040 0.001 1.1 0
Sig_1vs1_041 0.001 1.15 0
Sig_1vs1_042 0.001 1.2 0
Sig_1vs1_043 0.001 1.25 0
Sig_1vs1_044 0.001 1.3 0
Sig_1vs1_045 0.001 0.8 0.5
Sig_1vs1_046 0.001 0.85 0.5
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Sig_1vs1_047 0.001 0.9 0.5
Sig_1vs1_048 0.001 0.95 0.5
Sig_1vs1_049 0.001 1 0.5
Sig_1vs1_050 0.001 1.05 0.5
Sig_1vs1_051 0.001 1.1 0.5
Sig_1vs1_052 0.001 1.15 0.5
Sig_1vs1_053 0.001 1.2 0.5
Sig_1vs1_054 0.001 1.25 0.5
Sig_1vs1_055 0.001 1.3 0.5
Sig_1vs1_056 0.001 0.8 1
Sig_1vs1_057 0.001 0.85 1
Sig_1vs1_058 0.001 0.9 1
Sig_1vs1_059 0.001 0.95 1
Sig_1vs1_060 0.001 1 1
Sig_1vs1_061 0.001 1.05 1
Sig_1vs1_062 0.001 1.1 1
Sig_1vs1_063 0.001 1.15 1
Sig_1vs1_064 0.001 1.2 1
Sig_1vs1_065 0.001 1.25 1
Sig_1vs1_066 0.001 1.3 1
Sig_1vs1_067 0.005 0.8 0
Sig_1vs1_068 0.005 0.85 0
Sig_1vs1_069 0.005 0.9 0
Sig_1vs1_070 0.005 0.95 0
Sig_1vs1_071 0.005 1 0
Sig_1vs1_072 0.005 1.05 0
Sig_1vs1_073 0.005 1.1 0
Sig_1vs1_074 0.005 1.15 0
Sig_1vs1_075 0.005 1.2 0
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Sig_1vs1_076 0.005 1.25 0
Sig_1vs1_077 0.005 1.3 0
Sig_1vs1_078 0.005 0.8 0.5
Sig_1vs1_079 0.005 0.85 0.5
Sig_1vs1_080 0.005 0.9 0.5
Sig_1vs1_081 0.005 0.95 0.5
Sig_1vs1_082 0.005 1 0.5
Sig_1vs1_083 0.005 1.05 0.5
Sig_1vs1_084 0.005 1.1 0.5
Sig_1vs1_085 0.005 1.15 0.5
Sig_1vs1_086 0.005 1.2 0.5
Sig_1vs1_087 0.005 1.25 0.5
Sig_1vs1_088 0.005 1.3 0.5
Sig_1vs1_089 0.005 0.8 1
Sig_1vs1_090 0.005 0.85 1
Sig_1vs1_091 0.005 0.9 1
Sig_1vs1_092 0.005 0.95 1
Sig_1vs1_093 0.005 1 1
Sig_1vs1_094 0.005 1.05 1
Sig_1vs1_095 0.005 1.1 1
Sig_1vs1_096 0.005 1.15 1
Sig_1vs1_097 0.005 1.2 1
Sig_1vs1_098 0.005 1.25 1
Sig_1vs1_099 0.005 1.3 1
Sig_1vs1_100 0.01 0.8 0
Sig_1vs1_101 0.01 0.85 0
Sig_1vs1_102 0.01 0.9 0
Sig_1vs1_103 0.01 0.95 0
Sig_1vs1_104 0.01 1 0
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Sig_1vs1_105 0.01 1.05 0
Sig_1vs1_106 0.01 1.1 0
Sig_1vs1_107 0.01 1.15 0
Sig_1vs1_108 0.01 1.2 0
Sig_1vs1_109 0.01 1.25 0
Sig_1vs1_110 0.01 1.3 0
Sig_1vs1_111 0.01 0.8 0.5
Sig_1vs1_112 0.01 0.85 0.5
Sig_1vs1_113 0.01 0.9 0.5
Sig_1vs1_114 0.01 0.95 0.5
Sig_1vs1_115 0.01 1 0.5
Sig_1vs1_116 0.01 1.05 0.5
Sig_1vs1_117 0.01 1.1 0.5
Sig_1vs1_118 0.01 1.15 0.5
Sig_1vs1_119 0.01 1.2 0.5
Sig_1vs1_120 0.01 1.25 0.5
Sig_1vs1_121 0.01 1.3 0.5
Sig_1vs1_122 0.01 0.8 1
Sig_1vs1_123 0.01 0.85 1
Sig_1vs1_124 0.01 0.9 1
Sig_1vs1_125 0.01 0.95 1
Sig_1vs1_126 0.01 1 1
Sig_1vs1_127 0.01 1.05 1
Sig_1vs1_128 0.01 1.1 1
Sig_1vs1_129 0.01 1.15 1
Sig_1vs1_130 0.01 1.2 1
Sig_1vs1_131 0.01 1.25 1
Sig_1vs1_132 0.01 1.3 1
Sig_1vs1_133 0.05 0.8 0
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Sig_1vs1_134 0.05 0.85 0
Sig_1vs1_135 0.05 0.9 0
Sig_1vs1_136 0.05 0.95 0
Sig_1vs1_137 0.05 1 0
Sig_1vs1_138 0.05 1.05 0
Sig_1vs1_139 0.05 1.1 0
Sig_1vs1_140 0.05 1.15 0
Sig_1vs1_141 0.05 1.2 0
Sig_1vs1_142 0.05 1.25 0
Sig_1vs1_143 0.05 1.3 0
Sig_1vs1_144 0.05 0.8 0.5
Sig_1vs1_145 0.05 0.85 0.5
Sig_1vs1_146 0.05 0.9 0.5
Sig_1vs1_147 0.05 0.95 0.5
Sig_1vs1_148 0.05 1 0.5
Sig_1vs1_149 0.05 1.05 0.5
Sig_1vs1_150 0.05 1.1 0.5
Sig_1vs1_151 0.05 1.15 0.5
Sig_1vs1_152 0.05 1.2 0.5
Sig_1vs1_153 0.05 1.25 0.5
Sig_1vs1_154 0.05 1.3 0.5
Sig_1vs1_155 0.05 0.8 1
Sig_1vs1_156 0.05 0.85 1
Sig_1vs1_157 0.05 0.9 1
Sig_1vs1_158 0.05 0.95 1
Sig_1vs1_159 0.05 1 1
Sig_1vs1_160 0.05 1.05 1
Sig_1vs1_161 0.05 1.1 1
Sig_1vs1_162 0.05 1.15 1
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Sig_1vs1_163 0.05 1.2 1
Sig_1vs1_164 0.05 1.25 1
Sig_1vs1_165 0.05 1.3 1
Sig_1vs1_166 0.1 0.8 0
Sig_1vs1_167 0.1 0.85 0
Sig_1vs1_168 0.1 0.9 0
Sig_1vs1_169 0.1 0.95 0
Sig_1vs1_170 0.1 1 0
Sig_1vs1_171 0.1 1.05 0
Sig_1vs1_172 0.1 1.1 0
Sig_1vs1_173 0.1 1.15 0
Sig_1vs1_174 0.1 1.2 0
Sig_1vs1_175 0.1 1.25 0
Sig_1vs1_176 0.1 1.3 0
Sig_1vs1_177 0.1 0.8 0.5
Sig_1vs1_178 0.1 0.85 0.5
Sig_1vs1_179 0.1 0.9 0.5
Sig_1vs1_180 0.1 0.95 0.5
Sig_1vs1_181 0.1 1 0.5
Sig_1vs1_182 0.1 1.05 0.5
Sig_1vs1_183 0.1 1.1 0.5
Sig_1vs1_184 0.1 1.15 0.5
Sig_1vs1_185 0.1 1.2 0.5
Sig_1vs1_186 0.1 1.25 0.5
Sig_1vs1_187 0.1 1.3 0.5
Sig_1vs1_188 0.1 0.8 1
Sig_1vs1_189 0.1 0.85 1
Sig_1vs1_190 0.1 0.9 1
Sig_1vs1_191 0.1 0.95 1
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Sig_1vs1_192 0.1 1 1
Sig_1vs1_193 0.1 1.05 1
Sig_1vs1_194 0.1 1.1 1
Sig_1vs1_195 0.1 1.15 1
Sig_1vs1_196 0.1 1.2 1
Sig_1vs1_197 0.1 1.25 1
Sig_1vs1_198 0.1 1.3 1
Sig_1vs1_199 0.15 0.8 0
Sig_1vs1_200 0.15 0.85 0
Sig_1vs1_201 0.15 0.9 0
Sig_1vs1_202 0.15 0.95 0
Sig_1vs1_203 0.15 1 0
Sig_1vs1_204 0.15 1.05 0
Sig_1vs1_205 0.15 1.1 0
Sig_1vs1_206 0.15 1.15 0
Sig_1vs1_207 0.15 1.2 0
Sig_1vs1_208 0.15 1.25 0
Sig_1vs1_209 0.15 1.3 0
Sig_1vs1_210 0.15 0.8 0.5
Sig_1vs1_211 0.15 0.85 0.5
Sig_1vs1_212 0.15 0.9 0.5
Sig_1vs1_213 0.15 0.95 0.5
Sig_1vs1_214 0.15 1 0.5
Sig_1vs1_215 0.15 1.05 0.5
Sig_1vs1_216 0.15 1.1 0.5
Sig_1vs1_217 0.15 1.15 0.5
Sig_1vs1_218 0.15 1.2 0.5
Sig_1vs1_219 0.15 1.25 0.5
Sig_1vs1_220 0.15 1.3 0.5
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Sig_1vs1_221 0.15 0.8 1
Sig_1vs1_222 0.15 0.85 1
Sig_1vs1_223 0.15 0.9 1
Sig_1vs1_224 0.15 0.95 1
Sig_1vs1_225 0.15 1 1
Sig_1vs1_226 0.15 1.05 1
Sig_1vs1_227 0.15 1.1 1
Sig_1vs1_228 0.15 1.15 1
Sig_1vs1_229 0.15 1.2 1
Sig_1vs1_230 0.15 1.25 1
Sig_1vs1_231 0.15 1.3 1
Sig_1vs1_232 0.2 0.8 0
Sig_1vs1_233 0.2 0.85 0
Sig_1vs1_234 0.2 0.9 0
Sig_1vs1_235 0.2 0.95 0
Sig_1vs1_236 0.2 1 0
Sig_1vs1_237 0.2 1.05 0
Sig_1vs1_238 0.2 1.1 0
Sig_1vs1_239 0.2 1.15 0
Sig_1vs1_240 0.2 1.2 0
Sig_1vs1_241 0.2 1.25 0
Sig_1vs1_242 0.2 1.3 0
Sig_1vs1_243 0.2 0.8 0.5
Sig_1vs1_244 0.2 0.85 0.5
Sig_1vs1_245 0.2 0.9 0.5
Sig_1vs1_246 0.2 0.95 0.5
Sig_1vs1_247 0.2 1 0.5
Sig_1vs1_248 0.2 1.05 0.5
Sig_1vs1_249 0.2 1.1 0.5
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Sig_1vs1_250 0.2 1.15 0.5
Sig_1vs1_251 0.2 1.2 0.5
Sig_1vs1_252 0.2 1.25 0.5
Sig_1vs1_253 0.2 1.3 0.5
Sig_1vs1_254 0.2 0.8 1
Sig_1vs1_255 0.2 0.85 1
Sig_1vs1_256 0.2 0.9 1
Sig_1vs1_257 0.2 0.95 1
Sig_1vs1_258 0.2 1 1
Sig_1vs1_259 0.2 1.05 1
Sig_1vs1_260 0.2 1.1 1
Sig_1vs1_261 0.2 1.15 1
Sig_1vs1_262 0.2 1.2 1
Sig_1vs1_263 0.2 1.25 1
Sig_1vs1_264 0.2 1.3 1
Sig_1vs1_265 0.25 0.8 0
Sig_1vs1_266 0.25 0.85 0
Sig_1vs1_267 0.25 0.9 0
Sig_1vs1_268 0.25 0.95 0
Sig_1vs1_269 0.25 1 0
Sig_1vs1_270 0.25 1.05 0
Sig_1vs1_271 0.25 1.1 0
Sig_1vs1_272 0.25 1.15 0
Sig_1vs1_273 0.25 1.2 0
Sig_1vs1_274 0.25 1.25 0
Sig_1vs1_275 0.25 1.3 0
Sig_1vs1_276 0.25 0.8 0.5
Sig_1vs1_277 0.25 0.85 0.5
Sig_1vs1_278 0.25 0.9 0.5
A.1. Signature gene matrix - Candidates’ characterization 61
Sig_1vs1_279 0.25 0.95 0.5
Sig_1vs1_280 0.25 1 0.5
Sig_1vs1_281 0.25 1.05 0.5
Sig_1vs1_282 0.25 1.1 0.5
Sig_1vs1_283 0.25 1.15 0.5
Sig_1vs1_284 0.25 1.2 0.5
Sig_1vs1_285 0.25 1.25 0.5
Sig_1vs1_286 0.25 1.3 0.5
Sig_1vs1_287 0.25 0.8 1
Sig_1vs1_288 0.25 0.85 1
Sig_1vs1_289 0.25 0.9 1
Sig_1vs1_290 0.25 0.95 1
Sig_1vs1_291 0.25 1 1
Sig_1vs1_292 0.25 1.05 1
Sig_1vs1_293 0.25 1.1 1
Sig_1vs1_294 0.25 1.15 1
Sig_1vs1_295 0.25 1.2 1
Sig_1vs1_296 0.25 1.25 1
Sig_1vs1_297 0.25 1.3 1







CD8mix_001 0.54 0.41 0.05
CD8mix_002 0.12 0.69 0.19
CD8mix_003 0.28 0.24 0.47
CD8mix_004 0.53 0.36 0.1
CD8mix_005 0.28 0.31 0.41
CD8mix_006 0.22 0.55 0.23
CD8mix_007 0.36 0.44 0.2
CD8mix_008 0.19 0.45 0.37
CD8mix_009 0.09 0.44 0.47
CD8mix_010 0.43 0.23 0.34
CD8mix_011 0.74 0.02 0.24
CD8mix_012 0.31 0.35 0.34
CD8mix_013 0.08 0.4 0.52
CD8mix_014 0.48 0.14 0.38
CD8mix_015 0.06 0.55 0.4
CD8mix_016 0.63 0.01 0.36
CD8mix_017 0.59 0.16 0.25
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CD8mix_018 0.01 0.6 0.39
CD8mix_019 0.27 0.12 0.61
CD8mix_020 0.63 0.08 0.29
CD8mix_021 0.29 0.42 0.29
CD8mix_022 0.25 0.05 0.7
CD8mix_023 0.19 0.02 0.79
CD8mix_024 0.3 0.33 0.37
CD8mix_025 0.39 0.15 0.46
CD8mix_026 0.15 0.38 0.47
CD8mix_027 0.07 0.16 0.77
CD8mix_028 0.47 0.23 0.31
CD8mix_029 0.11 0.5 0.39
CD8mix_030 0.06 0.09 0.85
CD8mix_031 0.18 0.25 0.57
CD8mix_032 0.51 0.11 0.37
CD8mix_033 0.54 0.29 0.17
CD8mix_034 0.44 0.48 0.08
CD8mix_035 0.28 0.42 0.3
CD8mix_036 0.37 0.25 0.38
CD8mix_037 0.23 0.33 0.44
CD8mix_038 0.32 0.4 0.29
CD8mix_039 0.24 0.29 0.46
CD8mix_040 0.33 0.37 0.3
CD8mix_041 0.31 0.58 0.11
CD8mix_042 0.18 0.26 0.56
CD8mix_043 0.32 0.07 0.61
CD8mix_044 0.54 0.08 0.38
CD8mix_045 0.5 0.29 0.2
CD8mix_046 0.34 0.42 0.24
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CD8mix_047 0.48 0.26 0.26
CD8mix_048 0.44 0.23 0.33
CD8mix_049 0.49 0.34 0.18
CD8mix_050 0.31 0.18 0.51
CD8mix_051 0.03 0.52 0.45
CD8mix_052 0.54 0.18 0.27
CD8mix_053 0.1 0.42 0.47
CD8mix_054 0.74 0.17 0.09
CD8mix_055 0.49 0.3 0.22
CD8mix_056 0.3 0.32 0.38
CD8mix_057 0.01 0.5 0.49
CD8mix_058 0.16 0.6 0.24
CD8mix_059 0.38 0.4 0.23
CD8mix_060 0.61 0.03 0.36
CD8mix_061 0.56 0.43 0.01
CD8mix_062 0.07 0.34 0.59
CD8mix_063 0.1 0.35 0.55
CD8mix_064 0.24 0.53 0.23
CD8mix_065 0.34 0.26 0.39
CD8mix_066 0.36 0.22 0.42
CD8mix_067 0.51 0.3 0.19
CD8mix_068 0.5 0.2 0.3
CD8mix_069 0.36 0.37 0.27
CD8mix_070 0.36 0.39 0.25
CD8mix_071 0.44 0.19 0.37
CD8mix_072 0.32 0.57 0.11
CD8mix_073 0.15 0.59 0.26
CD8mix_074 0.12 0.49 0.39
CD8mix_075 0.14 0.08 0.78
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CD8mix_076 0.49 0.04 0.47
CD8mix_077 0.16 0.52 0.31
CD8mix_078 0.35 0.24 0.41
CD8mix_079 0.08 0.62 0.3
CD8mix_080 0.37 0.38 0.25
CD8mix_081 0.05 0.51 0.44
CD8mix_082 0.68 0.22 0.1
CD8mix_083 0.22 0.59 0.19
CD8mix_084 0.1 0.57 0.33
CD8mix_085 0.44 0.13 0.43
CD8mix_086 0.77 0.07 0.17
CD8mix_087 0.08 0.48 0.44
CD8mix_088 0.27 0.28 0.45
CD8mix_089 0.49 0.24 0.27
CD8mix_090 0.4 0.48 0.13
CD8mix_091 0.13 0.53 0.34
CD8mix_092 0.39 0.19 0.42
CD8mix_093 0.34 0.16 0.5
CD8mix_094 0.27 0.72 0.01
CD8mix_095 0.37 0.25 0.39
CD8mix_096 0.85 0.01 0.14
CD8mix_097 0.32 0.39 0.29
CD8mix_098 0.23 0.47 0.3
CD8mix_099 0.26 0.41 0.33
CD8mix_100 0.15 0.2 0.65
TABLE B.1: Simulation table to build all the mixture matrices.
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B.2 Overall deconvolutional results - CD8sig selection
Signature ID gene num RMSE all RMSE CM RMSE EM RMSE N corr all corr CM corr EM corr N
Sig_1vs1_001 254 0.3627 0.4644 0.1792 0.3833 0.0339 0.1861 0.4048 0.3662
Sig_1vs1_002 233 0.4006 0.5345 0.2194 0.3842 0.0247 0.0962 0.402 0.3103
Sig_1vs1_003 213 0.3668 0.4813 0.191 0.3681 0.0757 0.1866 0.4746 0.5419
Sig_1vs1_004 194 0.3056 0.3902 0.1784 0.3102 0.1377 0.2788 0.4254 0.6984
Sig_1vs1_005 175 0.2666 0.3263 0.1935 0.2634 0.1964 0.2543 0.3818 0.6214
Sig_1vs1_006 149 0.2315 0.2688 0.1852 0.2328 0.2263 0.2362 0.3953 0.5428
Sig_1vs1_007 126 0.3263 0.4236 0.1982 0.3175 0.1022 0.1653 0.3896 0.571
Sig_1vs1_008 101 0.3583 0.4647 0.2219 0.3462 -0.0176 -0.2185 0.1621 0.5458
Sig_1vs1_009 90 0.4304 0.591 0.3017 0.3397 0.0452 0.1952 0.2588 0.5792
Sig_1vs1_010 79 0.4377 0.6034 0.3139 0.3347 0.0536 0.2902 0.3944 0.5582
Sig_1vs1_011 71 0.4203 0.5784 0.2888 0.3348 0.06 0.2554 0.463 0.5254
Sig_1vs1_012 193 0.4922 0.6784 0.3448 0.3842 -0.0089 0.1598 0.389 0.4474
Sig_1vs1_013 179 0.5011 0.6904 0.3591 0.3843 -0.0187 0.1405 0.3113 0.4137
Sig_1vs1_014 166 0.504 0.6941 0.3634 0.3851 -0.0216 0.1829 0.2396 0.3789
Sig_1vs1_015 152 0.5079 0.699 0.3654 0.3897 -0.0279 -0.0606 -0.0575 0.299
Sig_1vs1_016 143 0.2603 0.3432 0.2023 0.2112 0.2188 0.1234 0.4639 0.5002
Sig_1vs1_017 130 0.2675 0.3569 0.2174 0.2002 0.2113 0.1478 0.4531 0.4943
Sig_1vs1_018 113 0.3298 0.4481 0.265 0.235 0.1278 0.1153 0.3639 0.523
Sig_1vs1_019 93 0.4548 0.6282 0.3237 0.3479 0.041 0.2754 0.4091 0.5689
Sig_1vs1_020 85 0.449 0.6198 0.3325 0.3318 0.0559 0.3671 0.4215 0.5833
Sig_1vs1_021 76 0.4406 0.6076 0.3206 0.3324 0.0573 0.3328 0.4289 0.5411
Sig_1vs1_022 69 0.4149 0.5709 0.2838 0.3318 0.0667 0.2551 0.478 0.5253
Sig_1vs1_023 82 0.2885 0.2827 0.2532 0.3251 0.2032 0.1472 0.2742 0.2498
Sig_1vs1_024 78 0.2942 0.2831 0.2561 0.3375 0.1774 0.1534 0.2793 0.1367
Sig_1vs1_025 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_026 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
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Sig_1vs1_027 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_028 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_029 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_030 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_031 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_032 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_033 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_034 276 0.3171 0.3724 0.1721 0.3652 0.0999 0.2722 0.4456 0.5623
Sig_1vs1_035 254 0.3506 0.447 0.1852 0.367 0.0776 0.1668 0.4364 0.5622
Sig_1vs1_036 225 0.3647 0.4726 0.186 0.3756 0.0673 0.1839 0.4577 0.5312
Sig_1vs1_037 205 0.3089 0.3853 0.1729 0.3286 0.1257 0.2671 0.4349 0.676
Sig_1vs1_038 183 0.2817 0.3419 0.1933 0.2896 0.1672 0.2633 0.3661 0.5877
Sig_1vs1_039 153 0.2559 0.3095 0.1869 0.2564 0.1982 0.2472 0.3913 0.5655
Sig_1vs1_040 129 0.3468 0.4558 0.208 0.3314 0.0917 0.1833 0.3923 0.5549
Sig_1vs1_041 102 0.3578 0.4641 0.2212 0.346 -0.0157 -0.2119 0.1665 0.5491
Sig_1vs1_042 91 0.4296 0.5899 0.3012 0.3391 0.0462 0.1967 0.2608 0.578
Sig_1vs1_043 80 0.4374 0.603 0.3134 0.3347 0.0538 0.2844 0.3955 0.5568
Sig_1vs1_044 72 0.4207 0.5789 0.289 0.335 0.0601 0.2551 0.4637 0.5244
Sig_1vs1_045 196 0.4917 0.6777 0.3442 0.384 -0.008 0.1692 0.3996 0.4107
Sig_1vs1_046 181 0.5009 0.6902 0.3589 0.3841 -0.0184 0.1421 0.3204 0.416
Sig_1vs1_047 167 0.5042 0.6944 0.3633 0.3854 -0.0219 0.1728 0.2382 0.3798
Sig_1vs1_048 153 0.5079 0.699 0.3654 0.3897 -0.0279 -0.0577 -0.0575 0.299
Sig_1vs1_049 144 0.2603 0.3429 0.2016 0.2122 0.2222 0.1368 0.4712 0.4971
Sig_1vs1_050 131 0.2673 0.3566 0.2168 0.2006 0.2094 0.1416 0.4538 0.4907
Sig_1vs1_051 114 0.3297 0.448 0.2646 0.2354 0.1275 0.1179 0.3635 0.5221
Sig_1vs1_052 94 0.4548 0.6282 0.3232 0.3483 0.0416 0.28 0.4135 0.5725
Sig_1vs1_053 86 0.4493 0.6202 0.3327 0.3321 0.0555 0.3628 0.4098 0.5824
Sig_1vs1_054 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_055 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
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Sig_1vs1_056 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_057 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_058 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_059 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_060 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_061 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_062 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_063 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_064 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_065 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_066 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_067 344 0.3825 0.2089 0.4934 0.3898 0.0448 0.4273 0.5337 NA
Sig_1vs1_068 314 0.4245 0.2577 0.5676 0.3898 0.0129 0.4102 0.3787 NA
Sig_1vs1_069 268 0.4513 0.3019 0.6066 0.3898 -0.0208 0.1305 0.3385 NA
Sig_1vs1_070 239 0.4609 0.3104 0.6236 0.3898 -0.026 0.1939 0.249 NA
Sig_1vs1_071 212 0.2877 0.3484 0.1931 0.2995 0.1581 0.2682 0.375 0.5263
Sig_1vs1_072 177 0.2591 0.3112 0.1862 0.2643 0.1974 0.2975 0.3914 0.5286
Sig_1vs1_073 141 0.3616 0.4775 0.2154 0.3435 0.0812 0.1782 0.396 0.508
Sig_1vs1_074 109 0.3908 0.519 0.2245 0.3719 -0.0176 -0.1651 0.2596 0.443
Sig_1vs1_075 94 0.4447 0.6115 0.3032 0.3569 0.0228 0.1254 0.3179 0.5491
Sig_1vs1_076 81 0.4389 0.6046 0.3124 0.3387 0.0466 0.2784 0.379 0.5459
Sig_1vs1_077 72 0.4207 0.5789 0.289 0.335 0.0601 0.2551 0.4637 0.5244
Sig_1vs1_078 212 0.496 0.6841 0.3563 0.3782 -0.0078 0.2477 0.3757 0.5168
Sig_1vs1_079 194 0.4994 0.6883 0.3577 0.383 -0.0164 0.1693 0.3269 0.4395
Sig_1vs1_080 175 0.5037 0.6937 0.3634 0.3846 -0.0212 0.1807 0.2288 0.3867
Sig_1vs1_081 159 0.5079 0.699 0.3654 0.3896 -0.0279 -0.0189 -0.0575 0.299
Sig_1vs1_082 149 0.2591 0.3403 0.2021 0.2116 0.2216 0.1338 0.4613 0.4971
Sig_1vs1_083 135 0.2689 0.3586 0.2167 0.2035 0.2051 0.1412 0.4401 0.4877
Sig_1vs1_084 115 0.3303 0.449 0.2651 0.2354 0.125 0.111 0.3574 0.5237
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Sig_1vs1_085 95 0.4543 0.6276 0.3221 0.3485 0.0426 0.2863 0.43 0.5691
Sig_1vs1_086 86 0.4493 0.6202 0.3327 0.3321 0.0555 0.3628 0.4098 0.5824
Sig_1vs1_087 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_088 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_089 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_090 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_091 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_092 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_093 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_094 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_095 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_096 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_097 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_098 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_099 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_100 380 0.1759 0.211 0.1479 0.1626 0.3737 0.3791 0.5826 0.5121
Sig_1vs1_101 349 0.1816 0.2162 0.147 0.1749 0.334 0.2983 0.5394 0.5307
Sig_1vs1_102 297 0.1898 0.2297 0.1548 0.1771 0.3296 0.4379 0.4974 0.6763
Sig_1vs1_103 257 0.1556 0.1799 0.1525 0.1306 0.4734 0.4937 0.5283 0.6932
Sig_1vs1_104 224 0.2254 0.2793 0.1719 0.2119 0.2058 0.3056 0.4833 0.4359
Sig_1vs1_105 186 0.192 0.2306 0.1641 0.1748 0.2627 0.2556 0.4951 0.4317
Sig_1vs1_106 149 0.2496 0.322 0.1904 0.2168 0.1402 0.2239 0.4853 0.4109
Sig_1vs1_107 115 0.4218 0.5741 0.2595 0.3698 -0.0079 -0.1715 0.292 0.515
Sig_1vs1_108 96 0.4756 0.6557 0.3488 0.3564 0.0204 0.4123 0.3133 0.5702
Sig_1vs1_109 82 0.4405 0.6067 0.3139 0.3399 0.0438 0.2781 0.3683 0.5419
Sig_1vs1_110 73 0.4208 0.5792 0.2887 0.3355 0.0591 0.2422 0.4558 0.5258
Sig_1vs1_111 213 0.496 0.6841 0.3567 0.3779 -0.0079 0.2457 0.3669 0.5179
Sig_1vs1_112 195 0.4992 0.6879 0.3573 0.383 -0.0159 0.1771 0.3343 0.438
Sig_1vs1_113 176 0.5036 0.6936 0.3634 0.3845 -0.021 0.1917 0.2366 0.3813
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Sig_1vs1_114 160 0.5079 0.699 0.3654 0.3896 -0.0279 -0.0148 -0.0575 0.299
Sig_1vs1_115 149 0.2591 0.3403 0.2021 0.2116 0.2216 0.1338 0.4613 0.4971
Sig_1vs1_116 135 0.2689 0.3586 0.2167 0.2035 0.2051 0.1412 0.4401 0.4877
Sig_1vs1_117 115 0.3303 0.449 0.2651 0.2354 0.125 0.111 0.3574 0.5237
Sig_1vs1_118 95 0.4543 0.6276 0.3221 0.3485 0.0426 0.2863 0.43 0.5691
Sig_1vs1_119 86 0.4493 0.6202 0.3327 0.3321 0.0555 0.3628 0.4098 0.5824
Sig_1vs1_120 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_121 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_122 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_123 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_124 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_125 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_126 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_127 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_128 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_129 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_130 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_131 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_132 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_133 53 0.2769 0.2918 0.2739 0.2647 0.1564 0.1389 0.3126 0.1056
Sig_1vs1_134 480 0.312 0.2036 0.3316 0.375 0.0189 0.1558 0.3916 0.3523
Sig_1vs1_135 402 0.3123 0.2017 0.3597 0.3501 0.0657 0.1719 0.4222 0.5702
Sig_1vs1_136 335 0.2972 0.1872 0.3615 0.315 0.1011 0.3169 0.4902 0.4937
Sig_1vs1_137 272 0.2843 0.3515 0.1622 0.3045 0.1107 0.2687 0.4964 0.2665
Sig_1vs1_138 212 0.2571 0.3253 0.1742 0.2493 0.1304 0.2635 0.4705 0.4063
Sig_1vs1_139 163 0.3127 0.4115 0.1964 0.2923 0.0783 0.2485 0.484 0.3519
Sig_1vs1_140 123 0.3144 0.1635 0.3673 0.3673 0.1078 0.4979 0.5116 0.5337
Sig_1vs1_141 99 0.4812 0.6634 0.3494 0.364 0.0106 0.3543 0.3058 0.5325
Sig_1vs1_142 83 0.4411 0.6077 0.3143 0.3401 0.0429 0.2709 0.3685 0.5433
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Sig_1vs1_143 74 0.4216 0.5802 0.2891 0.3362 0.0577 0.2377 0.4535 0.5226
Sig_1vs1_144 224 0.497 0.6851 0.356 0.3806 -0.009 0.2634 0.3098 0.5017
Sig_1vs1_145 205 0.4996 0.6884 0.3576 0.3833 -0.0134 0.2984 0.3816 0.491
Sig_1vs1_146 186 0.5049 0.6953 0.3631 0.3866 -0.023 0.169 0.2273 0.4194
Sig_1vs1_147 169 0.508 0.6991 0.3653 0.3898 -0.0281 -0.1862 -0.0371 NA
Sig_1vs1_148 153 0.258 0.3381 0.2044 0.2087 0.2205 0.1332 0.4217 0.5787
Sig_1vs1_149 138 0.2629 0.3496 0.2147 0.1974 0.195 0.0974 0.4185 0.5145
Sig_1vs1_150 116 0.3262 0.4436 0.2589 0.2353 0.1148 0.047 0.3586 0.518
Sig_1vs1_151 96 0.4566 0.6303 0.3237 0.3515 0.0346 0.246 0.3695 0.5446
Sig_1vs1_152 87 0.4512 0.6235 0.3299 0.3364 0.0592 0.3722 0.4366 0.6014
Sig_1vs1_153 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_154 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_155 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_156 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_157 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_158 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_159 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_160 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_161 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_162 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_163 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_164 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_165 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_166 53 0.2769 0.2918 0.2739 0.2647 0.1564 0.1389 0.3126 0.1056
Sig_1vs1_167 549 0.1933 0.1904 0.2159 0.171 0.3131 0.3362 0.4467 0.4663
Sig_1vs1_168 451 0.1936 0.2089 0.2183 0.1456 0.3255 0.3418 0.4389 0.5399
Sig_1vs1_169 367 0.1843 0.214 0.1916 0.1391 0.3307 0.3754 0.4258 0.5892
Sig_1vs1_170 289 0.1698 0.179 0.1648 0.1652 0.3833 0.3645 0.4975 0.3859
Sig_1vs1_171 220 0.164 0.181 0.1627 0.1465 0.4142 0.3133 0.4536 0.5125
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Sig_1vs1_172 169 0.3156 0.4149 0.1962 0.2971 0.0752 0.229 0.4804 0.328
Sig_1vs1_173 125 0.3148 0.1626 0.3658 0.3701 0.1068 0.5053 0.5339 0.4936
Sig_1vs1_174 100 0.4813 0.6635 0.3496 0.364 0.0107 0.357 0.3052 0.5321
Sig_1vs1_175 83 0.4411 0.6077 0.3143 0.3401 0.0429 0.2709 0.3685 0.5433
Sig_1vs1_176 74 0.4216 0.5802 0.2891 0.3362 0.0577 0.2377 0.4535 0.5226
Sig_1vs1_177 226 0.4971 0.6852 0.3563 0.3804 -0.0091 0.2627 0.3114 0.5031
Sig_1vs1_178 207 0.4997 0.6886 0.3579 0.3831 -0.0135 0.2907 0.3689 0.4927
Sig_1vs1_179 188 0.5049 0.6952 0.3632 0.3866 -0.0229 0.1714 0.2294 0.4205
Sig_1vs1_180 171 0.508 0.6991 0.3653 0.3898 -0.0281 -0.1796 -0.0212 0.2536
Sig_1vs1_181 155 0.2585 0.3391 0.2036 0.2098 0.225 0.1454 0.4301 0.5809
Sig_1vs1_182 139 0.2619 0.3483 0.2138 0.1967 0.2006 0.1119 0.4248 0.5267
Sig_1vs1_183 117 0.3265 0.4443 0.2582 0.2361 0.1151 0.0465 0.3614 0.5193
Sig_1vs1_184 97 0.4565 0.6302 0.3236 0.3512 0.0358 0.2535 0.3779 0.5512
Sig_1vs1_185 88 0.4501 0.6218 0.3295 0.3353 0.0618 0.3791 0.4336 0.6009
Sig_1vs1_186 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_187 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_188 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_189 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_190 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_191 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_192 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_193 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_194 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_195 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_196 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_197 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_198 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_199 53 0.2769 0.2918 0.2739 0.2647 0.1564 0.1389 0.3126 0.1056
Sig_1vs1_200 609 0.2281 0.2361 0.2683 0.1684 0.2232 0.3015 0.4374 0.4031
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Sig_1vs1_201 490 0.2537 0.3003 0.2786 0.1589 0.169 0.1507 0.3762 0.4142
Sig_1vs1_202 395 0.2358 0.29 0.2448 0.1508 0.1997 0.2577 0.3943 0.5243
Sig_1vs1_203 306 0.1866 0.1929 0.1944 0.1718 0.2868 0.2346 0.378 0.3839
Sig_1vs1_204 226 0.1651 0.1825 0.1632 0.1476 0.4086 0.3107 0.4486 0.517
Sig_1vs1_205 173 0.3147 0.4148 0.1999 0.2915 0.0769 0.2208 0.4811 0.337
Sig_1vs1_206 127 0.3168 0.1639 0.3696 0.3709 0.1066 0.4984 0.5241 0.4874
Sig_1vs1_207 100 0.4813 0.6635 0.3496 0.364 0.0107 0.357 0.3052 0.5321
Sig_1vs1_208 83 0.4411 0.6077 0.3143 0.3401 0.0429 0.2709 0.3685 0.5433
Sig_1vs1_209 74 0.4216 0.5802 0.2891 0.3362 0.0577 0.2377 0.4535 0.5226
Sig_1vs1_210 226 0.4971 0.6852 0.3563 0.3804 -0.0091 0.2627 0.3114 0.5031
Sig_1vs1_211 207 0.4997 0.6886 0.3579 0.3831 -0.0135 0.2907 0.3689 0.4927
Sig_1vs1_212 188 0.5049 0.6952 0.3632 0.3866 -0.0229 0.1714 0.2294 0.4205
Sig_1vs1_213 171 0.508 0.6991 0.3653 0.3898 -0.0281 -0.1796 -0.0212 0.2536
Sig_1vs1_214 155 0.2585 0.3391 0.2036 0.2098 0.225 0.1454 0.4301 0.5809
Sig_1vs1_215 139 0.2619 0.3483 0.2138 0.1967 0.2006 0.1119 0.4248 0.5267
Sig_1vs1_216 117 0.3265 0.4443 0.2582 0.2361 0.1151 0.0465 0.3614 0.5193
Sig_1vs1_217 97 0.4565 0.6302 0.3236 0.3512 0.0358 0.2535 0.3779 0.5512
Sig_1vs1_218 88 0.4501 0.6218 0.3295 0.3353 0.0618 0.3791 0.4336 0.6009
Sig_1vs1_219 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_220 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_221 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_222 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_223 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_224 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_225 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_226 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_227 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_228 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_229 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
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Sig_1vs1_230 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_231 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_232 53 0.2769 0.2918 0.2739 0.2647 0.1564 0.1389 0.3126 0.1056
Sig_1vs1_233 647 0.2514 0.2337 0.3137 0.1912 0.1869 0.3439 0.4395 0.4267
Sig_1vs1_234 514 0.2689 0.3107 0.3079 0.1602 0.145 0.1587 0.4092 0.3857
Sig_1vs1_235 408 0.2522 0.302 0.281 0.1438 0.1575 0.2021 0.3715 0.5281
Sig_1vs1_236 311 0.1952 0.1909 0.2056 0.1886 0.2471 0.2401 0.3672 0.363
Sig_1vs1_237 228 0.1647 0.1835 0.1618 0.1467 0.409 0.2983 0.4636 0.5094
Sig_1vs1_238 174 0.3158 0.4141 0.1939 0.3002 0.0718 0.2043 0.4746 0.3215
Sig_1vs1_239 127 0.3168 0.1639 0.3696 0.3709 0.1066 0.4984 0.5241 0.4874
Sig_1vs1_240 100 0.4813 0.6635 0.3496 0.364 0.0107 0.357 0.3052 0.5321
Sig_1vs1_241 83 0.4411 0.6077 0.3143 0.3401 0.0429 0.2709 0.3685 0.5433
Sig_1vs1_242 74 0.4216 0.5802 0.2891 0.3362 0.0577 0.2377 0.4535 0.5226
Sig_1vs1_243 226 0.4971 0.6852 0.3563 0.3804 -0.0091 0.2627 0.3114 0.5031
Sig_1vs1_244 207 0.4997 0.6886 0.3579 0.3831 -0.0135 0.2907 0.3689 0.4927
Sig_1vs1_245 188 0.5049 0.6952 0.3632 0.3866 -0.0229 0.1714 0.2294 0.4205
Sig_1vs1_246 171 0.508 0.6991 0.3653 0.3898 -0.0281 -0.1796 -0.0212 0.2536
Sig_1vs1_247 155 0.2585 0.3391 0.2036 0.2098 0.225 0.1454 0.4301 0.5809
Sig_1vs1_248 139 0.2619 0.3483 0.2138 0.1967 0.2006 0.1119 0.4248 0.5267
Sig_1vs1_249 117 0.3265 0.4443 0.2582 0.2361 0.1151 0.0465 0.3614 0.5193
Sig_1vs1_250 97 0.4565 0.6302 0.3236 0.3512 0.0358 0.2535 0.3779 0.5512
Sig_1vs1_251 88 0.4501 0.6218 0.3295 0.3353 0.0618 0.3791 0.4336 0.6009
Sig_1vs1_252 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_253 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_254 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
Sig_1vs1_255 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_256 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_257 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_258 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
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Sig_1vs1_259 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_260 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_261 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_262 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_263 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_264 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vs1_265 53 0.2769 0.2918 0.2739 0.2647 0.1564 0.1389 0.3126 0.1056
Sig_1vs1_266 53 0.2769 0.2918 0.2739 0.2647 0.1564 0.1389 0.3126 0.1056
Sig_1vs1_267 543 0.2749 0.3097 0.316 0.1758 0.123 0.1377 0.3929 0.2633
Sig_1vs1_268 427 0.2582 0.3052 0.2863 0.1579 0.1342 0.1327 0.3908 0.3697
Sig_1vs1_269 323 0.1966 0.2004 0.2015 0.1875 0.2333 0.1666 0.3811 0.2633
Sig_1vs1_270 232 0.1723 0.1914 0.1608 0.1629 0.3458 0.1742 0.4695 0.3669
Sig_1vs1_271 175 0.317 0.416 0.1964 0.2998 0.0696 0.1974 0.4654 0.3196
Sig_1vs1_272 128 0.3164 0.166 0.3676 0.371 0.1038 0.4835 0.5176 0.4794
Sig_1vs1_273 100 0.4813 0.6635 0.3496 0.364 0.0107 0.357 0.3052 0.5321
Sig_1vs1_274 83 0.4411 0.6077 0.3143 0.3401 0.0429 0.2709 0.3685 0.5433
Sig_1vs1_275 74 0.4216 0.5802 0.2891 0.3362 0.0577 0.2377 0.4535 0.5226
Sig_1vs1_276 226 0.4971 0.6852 0.3563 0.3804 -0.0091 0.2627 0.3114 0.5031
Sig_1vs1_277 207 0.4997 0.6886 0.3579 0.3831 -0.0135 0.2907 0.3689 0.4927
Sig_1vs1_278 188 0.5049 0.6952 0.3632 0.3866 -0.0229 0.1714 0.2294 0.4205
Sig_1vs1_279 171 0.508 0.6991 0.3653 0.3898 -0.0281 -0.1796 -0.0212 0.2536
Sig_1vs1_280 155 0.2585 0.3391 0.2036 0.2098 0.225 0.1454 0.4301 0.5809
Sig_1vs1_281 139 0.2619 0.3483 0.2138 0.1967 0.2006 0.1119 0.4248 0.5267
Sig_1vs1_282 117 0.3265 0.4443 0.2582 0.2361 0.1151 0.0465 0.3614 0.5193
Sig_1vs1_283 97 0.4565 0.6302 0.3236 0.3512 0.0358 0.2535 0.3779 0.5512
Sig_1vs1_284 88 0.4501 0.6218 0.3295 0.3353 0.0618 0.3791 0.4336 0.6009
Sig_1vs1_285 77 0.4402 0.6069 0.32 0.3325 0.058 0.3368 0.4249 0.543
Sig_1vs1_286 70 0.4145 0.5702 0.2827 0.3321 0.066 0.2467 0.4772 0.5246
Sig_1vs1_287 83 0.2888 0.2831 0.2533 0.3256 0.2012 0.1423 0.2741 0.2481
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Sig_1vs1_288 79 0.2943 0.2836 0.2567 0.337 0.1744 0.1473 0.279 0.1328
Sig_1vs1_289 77 0.2934 0.2821 0.2562 0.3361 0.1771 0.1536 0.2795 0.1347
Sig_1vs1_290 74 0.3278 0.3234 0.2535 0.3919 0.1211 0.0179 0.2947 0.0529
Sig_1vs1_291 73 0.327 0.3155 0.2521 0.397 0.172 0.0923 0.2844 0.2221
Sig_1vs1_292 69 0.3338 0.3225 0.2531 0.4077 0.1504 0.0616 0.2862 0.1545
Sig_1vs1_293 67 0.3335 0.3226 0.2536 0.4065 0.148 0.0595 0.2803 0.1491
Sig_1vs1_294 62 0.2847 0.3036 0.2744 0.275 0.1384 0.1153 0.2982 0.0861
Sig_1vs1_295 58 0.2765 0.2927 0.2735 0.2625 0.1604 0.149 0.3193 0.1187
Sig_1vs1_296 56 0.2764 0.2926 0.2739 0.2617 0.1573 0.1398 0.3116 0.1232
Sig_1vs1_297 52 0.2768 0.2915 0.2739 0.2643 0.1515 0.1387 0.315 0.1005
Sig_1vsall_001 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_002 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_003 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_004 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_005 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_006 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_007 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_008 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_009 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_010 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_011 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_012 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_013 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_014 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_015 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_016 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_017 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_018 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_019 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
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Sig_1vsall_020 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_021 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_022 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_023 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_024 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_025 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_026 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_027 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_028 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_029 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_030 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_031 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_032 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_033 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_034 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_035 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_036 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_037 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_038 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_039 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_040 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_041 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_042 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_043 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_044 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_045 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_046 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_047 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_048 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
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Sig_1vsall_049 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_050 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_051 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_052 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_053 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_054 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_055 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_056 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_057 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_058 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_059 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_060 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_061 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_062 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_063 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_064 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_065 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_066 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_067 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_068 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_069 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_070 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_071 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_072 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_073 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_074 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_075 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_076 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_077 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
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Sig_1vsall_078 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_079 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_080 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_081 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_082 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_083 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_084 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_085 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_086 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_087 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_088 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_089 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_090 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_091 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_092 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_093 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_094 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_095 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_096 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_097 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_098 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_099 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_100 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_101 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_102 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_103 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_104 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_105 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_106 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
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Sig_1vsall_107 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_108 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_109 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_110 399 0.2057 0.217 0.2106 0.1883 0.2276 0.1153 0.3612 0.3181
Sig_1vsall_111 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_112 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_113 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_114 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_115 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_116 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_117 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_118 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_119 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_120 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_121 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_122 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_123 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_124 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_125 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_126 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_127 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_128 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_129 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_130 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_131 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_132 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_133 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_134 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_135 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
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Sig_1vsall_136 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_137 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_138 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_139 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_140 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_141 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_142 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_143 401 0.2056 0.2174 0.21 0.1882 0.2286 0.1094 0.3641 0.3232
Sig_1vsall_144 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_145 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_146 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_147 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_148 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_149 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_150 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_151 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_152 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_153 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_154 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_155 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_156 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_157 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_158 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_159 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_160 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_161 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_162 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_163 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_164 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
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Sig_1vsall_165 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_166 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_167 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_168 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_169 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_170 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_171 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_172 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_173 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_174 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_175 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_176 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_177 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_178 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_179 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_180 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_181 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_182 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_183 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_184 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_185 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_186 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_187 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_188 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_189 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_190 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_191 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_192 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_193 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
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Sig_1vsall_194 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_195 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_196 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_197 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_198 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_199 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_200 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_201 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_202 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_203 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_204 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_205 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_206 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_207 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_208 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_209 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_210 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_211 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_212 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_213 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_214 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_215 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_216 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_217 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_218 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_219 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_220 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_221 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_222 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
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Sig_1vsall_223 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_224 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_225 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_226 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_227 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_228 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_229 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_230 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_231 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_232 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_233 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_234 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_235 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_236 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_237 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_238 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_239 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_240 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_241 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_242 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_243 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_244 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_245 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_246 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_247 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_248 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_249 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_250 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_251 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
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Sig_1vsall_252 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_253 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_254 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_255 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_256 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_257 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_258 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_259 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_260 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_261 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_262 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_263 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_264 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_265 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_266 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_267 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_268 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_269 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_270 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_271 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_272 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_273 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_274 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_275 402 0.2056 0.2171 0.2105 0.1881 0.2293 0.1111 0.3635 0.325
Sig_1vsall_276 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_277 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_278 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_279 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_280 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
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Sig_1vsall_281 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_282 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_283 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_284 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_285 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_286 396 0.2052 0.2164 0.2109 0.1872 0.229 0.1161 0.3584 0.317
Sig_1vsall_287 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_288 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_289 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_290 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_291 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_292 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_293 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_294 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_295 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_296 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
Sig_1vsall_297 305 0.205 0.2249 0.2195 0.1652 0.2339 0.1114 0.3277 0.3596
TABLE B.2: Performances obtained by CD8quant in the deconvolu-
tion of the Pulko simulated mixtures using different signature ma-
trix derived from the Bonnal data set. The first column offers each
signature candidate which has been fed the algorithm, while the
other columns present the signature genes for each candidate and
the RMSE and Pearson’s correlation output between the real fractions




[1] O. K. Afanasiev et al. “Vascular E-selectin expression correlates with CD8 lym-
phocyte infiltration and improved outcome in Merkel cell carcinoma”. In: Jour-
nal of Investigative Dermatology 133.8 (2013), pp. 2065–2073.
[2] M. Angelova et al. “Characterization of the immunophenotypes and antigenomes
of colorectal cancers reveals distinct tumor escape mechanisms and novel tar-
gets for immunotherapy”. In: Genome biology 16.1 (2015), p. 64.
[3] S. M. Ansell et al. “PD-1 blockade with nivolumab in relapsed or refractory
Hodgkin’s lymphoma”. In: New England Journal of Medicine 372.4 (2015), pp. 311–
319.
[4] C. W. Brennan et al. “The somatic genomic landscape of glioblastoma”. In: Cell
155.2 (2013), pp. 462–477.
[5] A. E. Carpenter et al. “CellProfiler: image analysis software for identifying and
quantifying cell phenotypes”. In: Genome biology 7.10 (2006), R100.
[6] P. Charoentong et al. “Pan-cancer immunogenomic analyses reveal genotype-
immunophenotype relationships and predictors of response to checkpoint block-
ade”. In: Cell reports 18.1 (2017), pp. 248–262.
[7] C. Conrad et al. “Plasmacytoid dendritic cells promote immunosuppression in
ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells”. In: Cancer
research 72.20 (2012), pp. 5240–5249.
[8] A. Dander et al. “Personalized Oncology Suite: integrating next-generation se-
quencing data and whole-slide bioimages”. In: BMC bioinformatics 15.1 (2014),
p. 306.
90 BIBLIOGRAPHY
[9] S. S. Dave et al. “Prediction of survival in follicular lymphoma based on molec-
ular features of tumor-infiltrating immune cells”. In: New England Journal of
Medicine 351.21 (2004), pp. 2159–2169.
[10] M. De Simone et al. “Transcriptional landscape of human tissue lymphocytes
unveils uniqueness of tumor-infiltrating T regulatory cells”. In: Immunity 45.5
(2016), pp. 1135–1147.
[11] M.-C. Dieu-Nosjean et al. “Tertiary lymphoid structures in cancer and beyond”.
In: Trends in immunology 35.11 (2014), pp. 571–580.
[12] A. Esteve-Codina et al. “A Comparison of RNA-Seq Results from Paired Formalin-
Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples”. In:
PloS one 12.1 (2017), e0170632.
[13] D. L. Farber, N. A. Yudanin, and N. P. Restifo. “Human memory T cells: genera-
tion, compartmentalization and homeostasis”. In: Nature reviews Immunology
14.1 (2014), pp. 24–35.
[14] M.-T. Fernández-Figueras et al. “Expression profiles associated with aggressive
behavior in Merkel cell carcinoma”. In: Modern Pathology 20.1 (2007), pp. 90–
101.
[15] F. Finotello and B. Di Camillo. “Measuring differential gene expression with
RNA-seq: challenges and strategies for data analysis”. In: Briefings in functional
genomics 14.2 (2015), pp. 130–142.
[16] W. H. Fridman et al. “The immune contexture in human tumours: impact on
clinical outcome”. In: Nature Reviews Cancer 12.4 (2012), pp. 298–306.
[17] J. Galon et al. “Cancer classification using the Immunoscore: a worldwide task
force”. In: Journal of translational medicine 10.1 (2012), p. 205.
[18] L. Gattinoni et al. “A human memory T cell subset with stem cell-like proper-
ties”. In: Nature medicine 17.10 (2011), pp. 1290–1297.
[19] V. Golubovskaya and L. Wu. “Different subsets of T cells, memory, effector func-
tions, and CAR-T immunotherapy”. In: Cancers 8.3 (2016), p. 36.
BIBLIOGRAPHY 91
[20] G. R. Gouveia et al. “Comparison of two methods of RNA extraction from formalin-
fixed paraffin-embedded tissue specimens”. In: BioMed research international
2014 (2014).
[21] H. Hackl et al. “Computational genomics tools for dissecting tumour-immune
cell interactions”. In: Nature Reviews Genetics (2016).
[22] S. Hadrup, M. Donia, and P. thor Straten. “Effector CD4 and CD8 T cells and
their role in the tumor microenvironment”. In: Cancer Microenvironment 6.2
(2013), pp. 123–133.
[23] J. Hedegaard et al. “Next-generation sequencing of RNA and DNA isolated from
paired fresh-frozen and formalin-fixed paraffin-embedded samples of human
cancer and normal tissue”. In: PloS one 9.5 (2014), e98187.
[24] G. Hennig et al. “Automated extraction of DNA and RNA from a single formalin-
fixed paraffin-embedded tissue section for analysis of both single-nucleotide
polymorphisms and mRNA expression”. In: Clinical chemistry 56.12 (2010), pp. 1845–
1853.
[25] L. Kamentsky et al. “Improved structure, function and compatibility for Cell-
Profiler: modular high-throughput image analysis software”. In: Bioinformatics
27.8 (2011), pp. 1179–1180.
[26] H Li. seqtk Toolkit for processing sequences in FASTA/Q formats. 2012.
[27] M. Linkert et al. “Metadata matters: access to image data in the real world”. In:
The Journal of cell biology 189.5 (2010), pp. 777–782.
[28] M. I. Love, W. Huber, and S. Anders. “Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2”. In: Genome biology 15.12 (2014),
p. 550.
[29] F. Lüder Ripoli et al. “A comparison of fresh frozen vs. formalin-fixed, paraffin-
embedded specimens of canine mammary tumors via branched-DNA assay”.
In: International journal of molecular sciences 17.5 (2016), p. 724.
[30] Y. D. Mahnke et al. “The who’s who of T-cell differentiation: Human memory T-
cell subsets”. In: European journal of immunology 43.11 (2013), pp. 2797–2809.
92 BIBLIOGRAPHY
[31] A. M. Newman et al. “Robust enumeration of cell subsets from tissue expression
profiles”. In: Nature methods 12.5 (2015), pp. 453–457.
[32] J. J. Obar and L. Lefrançois. “Memory CD8+ T cell differentiation”. In: Annals of
the New York Academy of Sciences 1183.1 (2010), pp. 251–266.
[33] B. A. Olenchock et al. “Disruption of diacylglycerol metabolism impairs the in-
duction of T cell anergy”. In: Nature immunology 7.11 (2006), pp. 1174–1181.
[34] F. Ozsolak and P. M. Milos. “RNA sequencing: advances, challenges and oppor-
tunities”. In: Nature reviews genetics 12.2 (2010), nrg2934.
[35] D. M. Pardoll. “Inducing autoimmune disease to treat cancer”. In: Proceedings
of the National Academy of Sciences 96.10 (1999), pp. 5340–5342.
[36] D. M. Pardoll. “The blockade of immune checkpoints in cancer immunother-
apy”. In: Nature Reviews Cancer 12.4 (2012), pp. 252–264.
[37] J Parker et al. “A supervised risk predictor of breast cancer based on biologi-
cal subtypes”. In: Journal of Clinical Oncology 26.15_suppl (2008), pp. 11008–
11008.
[38] J. S. Parker et al. “Supervised risk predictor of breast cancer based on intrinsic
subtypes”. In: Journal of clinical oncology 27.8 (2009), pp. 1160–1167.
[39] S. K. Penland et al. “RNA expression analysis of formalin-fixed paraffin-embedded
tumors”. In: Laboratory investigation 87.4 (2007), pp. 383–391.
[40] P. A. Prieto et al. “CTLA-4 blockade with ipilimumab: long-term follow-up of
177 patients with metastatic melanoma”. In: Clinical Cancer Research (2012).
[41] V. Pulko et al. “Human memory T cells with a naive phenotype accumulate with
aging and respond to persistent viruses”. In: Nature immunology 17.8 (2016),
pp. 966–975.
[42] M. D. Robinson, D. J. McCarthy, and G. K. Smyth. “edgeR: a Bioconductor pack-
age for differential expression analysis of digital gene expression data”. In: Bioin-
formatics 26.1 (2010), pp. 139–140.
BIBLIOGRAPHY 93
[43] C. Sautès-Fridman et al. “Tertiary lymphoid structures in cancers: prognostic
value, regulation, and manipulation for therapeutic intervention”. In: Frontiers
in immunology 7 (2016).
[44] M. S. Scicchitano et al. “Preliminary comparison of quantity, quality, and mi-
croarray performance of RNA extracted from formalin-fixed, paraffin-embedded,
and unfixed frozen tissue samples”. In: Journal of Histochemistry & Cytochem-
istry 54.11 (2006), pp. 1229–1237.
[45] A. P. Scorsato and J. E. Q. Telles. “Fatores que interferem na qualidade do DNA
extraído de amostras biológicas armazenadas em blocos de parafina”. In: Jornal
Brasileiro de Patologia e Medicina Laboratorial 47.5 (2011), pp. 541–548.
[46] B. Sengüven et al. “Comparison of methods for the extraction of DNA from
formalin-fixed, paraffin-embedded archival tissues”. In: International journal
of medical sciences 11.5 (2014), p. 494.
[47] C. Sommer et al. “Ilastik: Interactive learning and segmentation toolkit”. In:
Biomedical Imaging: From Nano to Macro, 2011 IEEE International Symposium
on. IEEE. 2011, pp. 230–233.
[48] E. Tappeiner et al. “TIminer: NGS data mining pipeline for cancer immunology
and immunotherapy”. In: Bioinformatics (2017).
[49] T. Tsujikawa et al. “Quantitative Multiplex Immunohistochemistry Reveals Myeloid-
Inflamed Tumor-Immune Complexity Associated with Poor Prognosis”. In: Cell
Reports 19.1 (2017), pp. 203–217.
[50] S. Von Ahlfen et al. “Determinants of RNA quality from FFPE samples”. In: PloS
one 2.12 (2007), e1261.
[51] Z. Wang, M. Gerstein, and M. Snyder. “RNA-Seq: a revolutionary tool for tran-
scriptomics”. In: Nature reviews genetics 10.1 (2009), pp. 57–63.
